WO2009024763A2 - Combination therapy - Google Patents
Combination therapy Download PDFInfo
- Publication number
- WO2009024763A2 WO2009024763A2 PCT/GB2008/002775 GB2008002775W WO2009024763A2 WO 2009024763 A2 WO2009024763 A2 WO 2009024763A2 GB 2008002775 W GB2008002775 W GB 2008002775W WO 2009024763 A2 WO2009024763 A2 WO 2009024763A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sirt1
- composition according
- polypeptide
- molecule
- nucleic acid
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title description 2
- 108010041191 Sirtuin 1 Proteins 0.000 claims abstract description 157
- 102000000344 Sirtuin 1 Human genes 0.000 claims abstract description 157
- 238000000034 method Methods 0.000 claims abstract description 107
- 238000011282 treatment Methods 0.000 claims abstract description 35
- 230000000694 effects Effects 0.000 claims abstract description 31
- 238000003745 diagnosis Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 158
- 206010028980 Neoplasm Diseases 0.000 claims description 64
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 63
- 229960002949 fluorouracil Drugs 0.000 claims description 59
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 claims description 53
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 claims description 53
- 238000006366 phosphorylation reaction Methods 0.000 claims description 51
- 230000026731 phosphorylation Effects 0.000 claims description 50
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 49
- 150000007523 nucleic acids Chemical class 0.000 claims description 48
- 201000011510 cancer Diseases 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 42
- 108020004999 messenger RNA Proteins 0.000 claims description 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 36
- 229920001184 polypeptide Polymers 0.000 claims description 34
- 102000039446 nucleic acids Human genes 0.000 claims description 32
- 108020004707 nucleic acids Proteins 0.000 claims description 32
- 239000013598 vector Substances 0.000 claims description 31
- 102000053602 DNA Human genes 0.000 claims description 26
- 108020004414 DNA Proteins 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 229920002477 rna polymer Polymers 0.000 claims description 23
- 229940079593 drug Drugs 0.000 claims description 21
- 102000011990 Sirtuin Human genes 0.000 claims description 20
- 108050002485 Sirtuin Proteins 0.000 claims description 20
- 239000002246 antineoplastic agent Substances 0.000 claims description 19
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
- 229940127089 cytotoxic agent Drugs 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 15
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 14
- 230000004048 modification Effects 0.000 claims description 14
- 238000012986 modification Methods 0.000 claims description 14
- 239000000523 sample Substances 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 12
- 210000002919 epithelial cell Anatomy 0.000 claims description 12
- 125000000539 amino acid group Chemical group 0.000 claims description 11
- 210000001072 colon Anatomy 0.000 claims description 11
- 238000009396 hybridization Methods 0.000 claims description 11
- 230000003612 virological effect Effects 0.000 claims description 11
- 241000701806 Human papillomavirus Species 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000000692 anti-sense effect Effects 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 108020004459 Small interfering RNA Proteins 0.000 claims description 6
- 235000008191 folinic acid Nutrition 0.000 claims description 6
- 239000011672 folinic acid Substances 0.000 claims description 6
- 229960001691 leucovorin Drugs 0.000 claims description 6
- 230000003463 hyperproliferative effect Effects 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 4
- 230000008901 benefit Effects 0.000 claims description 4
- 239000013068 control sample Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 3
- 108091081021 Sense strand Proteins 0.000 claims description 3
- 230000001399 anti-metabolic effect Effects 0.000 claims description 3
- 229960004117 capecitabine Drugs 0.000 claims description 3
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 3
- 150000003230 pyrimidines Chemical class 0.000 claims description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 108091005601 modified peptides Proteins 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 230000006659 positive regulation of apoptotic process Effects 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims description 2
- 229940104230 thymidine Drugs 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 79
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 79
- 108090000623 proteins and genes Proteins 0.000 description 33
- 102220393251 c.79T>C Human genes 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 241000282414 Homo sapiens Species 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 20
- 102200054149 rs397515527 Human genes 0.000 description 18
- 238000001890 transfection Methods 0.000 description 18
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 17
- 206010009944 Colon cancer Diseases 0.000 description 16
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 16
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 16
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 10
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 10
- 230000030279 gene silencing Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 201000009030 Carcinoma Diseases 0.000 description 9
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 9
- 230000009368 gene silencing by RNA Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 235000004400 serine Nutrition 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000005754 cellular signaling Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 230000003362 replicative effect Effects 0.000 description 8
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 101100023501 Homo sapiens MAPK9 gene Proteins 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 108700025695 Suppressor Genes Proteins 0.000 description 5
- 238000006640 acetylation reaction Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 5
- 201000010989 colorectal carcinoma Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108010033040 Histones Proteins 0.000 description 4
- 230000021736 acetylation Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000654472 Homo sapiens NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 3
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 3
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 102000002569 MAP Kinase Kinase 4 Human genes 0.000 description 3
- 108010068304 MAP Kinase Kinase 4 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 238000003197 gene knockdown Methods 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 102000056482 human SIRT1 Human genes 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 2
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 description 2
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 2
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 description 2
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 2
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 2
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 2
- 241000598171 Human adenovirus sp. Species 0.000 description 2
- 102100031612 Hypermethylated in cancer 1 protein Human genes 0.000 description 2
- 101710133850 Hypermethylated in cancer 1 protein Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 2
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 2
- 108010001441 Phosphopeptides Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 102000005497 Thymidylate Synthase Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 210000001599 sigmoid colon Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical class NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016559 DNA Primase Human genes 0.000 description 1
- 108010092681 DNA Primase Proteins 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102100032257 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 241000701828 Human papillomavirus type 11 Species 0.000 description 1
- 241000709704 Human poliovirus 2 Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000012825 JNK inhibitor Substances 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 108700027653 Mitogen-Activated Protein Kinase 9 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 1
- MXNRLFUSFKVQSK-QMMMGPOBSA-O N(6),N(6),N(6)-trimethyl-L-lysine Chemical compound C[N+](C)(C)CCCC[C@H]([NH3+])C([O-])=O MXNRLFUSFKVQSK-QMMMGPOBSA-O 0.000 description 1
- XXEWFEBMSGLYBY-ZETCQYMHSA-N N(6),N(6)-dimethyl-L-lysine Chemical compound CN(C)CCCC[C@H](N)C(O)=O XXEWFEBMSGLYBY-ZETCQYMHSA-N 0.000 description 1
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 1
- PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 102100026531 Prelamin-A/C Human genes 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000012338 Therapeutic targeting Methods 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000007960 cellular response to stress Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000018554 digestive system carcinoma Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006543 gametophyte development Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 1
- 201000004528 gastrointestinal lymphoma Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 101150024228 mdm2 gene Proteins 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000030940 penile carcinoma Diseases 0.000 description 1
- 201000008174 penis carcinoma Diseases 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003384 transverse colon Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
Definitions
- the invention relates to a treatment regime suitable to control the activity of a sirtuin, for example SIRT1, typically in the treatment of hyperproliferative diseases such as cancer; and including diagnostic tests that detects differential phosphorylation of sirtuin polypeptides.
- a sirtuin for example SIRT1
- diagnostic tests that detects differential phosphorylation of sirtuin polypeptides.
- Apoptosis is a process by which multi-cellular organisms regulate cell number and differentiation. The process is regulated by factors which either induce or prevent apoptosis.
- Tumour suppressor proteins have pro-apoptotic activities.
- Tumour suppressor genes encode proteins which function to inhibit cell growth or division and are therefore important with respect to maintaining proliferation, growth and differentiation of normal cells. Mutations in tumour suppressor genes result in abnormal cell-cycle progression whereby the normal cell-cycle check points which arrest the cell- cycle, when, for example, DNA is damaged, are ignored and damaged cells divide uncontrollably.
- the products of tumour suppressor genes function in all parts of the cell (e.g. cell surface, cytoplasm, mitochondrion and nucleus) and prevent the passage of damaged cells through the cell- cycle.
- the tumour suppressor gene which has been the subject of the most intense research is p53.
- p53 encodes a protein which functions as a transcription factor and is a key regulator of the cell division cycle. It was discovered in 1978 as a protein shown to bind with affinity to the SV40 large T antigen.
- the p53 gene encodes a 393 amino acid polypeptide with a molecular weight of 53kDa.
- Genes regulated by the transcriptional activity of p53 contain a p53 recognition sequence in their 5' regions. These genes are activated when the cellular levels of p53 are elevated due to, for example, DNA damage. Examples of genes that respond to p53 include, mdm2, Bax and PIG-3. Bax and PIG-3 are involved in one of the most important functions of p53, the induction of apoptosis.
- SIRT1 a class III histone de-acetylase able to regulate gene expression at several levels.
- linker histone H1 by SIRT1 enables heterochromatin formation and associated gene silencing 16 .
- SIRT1 also deacetylates core histone H3 and recruitment of SIRT1 to specific promoters results in selective gene silencing 17 ' 18 .
- SIRT1 targets several non-histone transcription regulators including the tumour suppressor p53 19 ' 20 . De-acetylation of p53 by SIRT1 down-regulates the pro-apoptotic p53 stress response 11 .
- SIRT1 and p53 thus counterbalance the cellular response to stress. This balance is dependent upon cellular levels of SIRT1 and p53 since over- expression favours cell survival or apoptosis respectively. Expression levels of p53 and SIRT1 therefore require stringent control. For p53 this is largely achieved through regulation of p53 protein stability 21 ' 22 .
- SIRT1 a transcriptional feed-back mechanism operates in which SIRT1 forms a complex with the transcription repressor hypermethylated in cancer 1 (HIC1) and selectively suppresses transcription from the SIRT1 promoter 12 ' 13 .
- SIRT1 expression is also regulated at the level of mRNA stability via the RNA-binding protein HuR which binds and stabilises SIRT1 mRNA 14 ' 15 .
- JNK Mitogen Activated Protein Kinase
- JNK1 produces four isoforms
- JNK2 also produces four isoforms
- JNK3 produces 2 isoforms.
- the different JNK isoforms differ in the protein substrates that they modify. Inhibitors of JNK are well known in the art.
- WO2005/074921 which is incorporated by reference in its entirety, describes a pyrazolanthone inhibitor of JNK2 and its use in the treatment of atherosclerosis.
- JNK inhibitors specific to each JNK kinase for example see Calbiochem kinase inhibitors at http://www.emdbiosciences.com/html/CBC/home.html: in particular for JNK2 specific inhibitors see Bennett et al 2001 Proc Natl Acad Sci USA 98, p13681; Han et a/ 2001, J Clin. Invest 108, p73; Shin et al 2002 Biochim Biophys. Acta, 1589, p311; which are incorporated by reference in their entirety.
- Chemotherapeutic agents are generally more effective at killing cancer cells than normal cells. Examples of these agents are well known in the art, some of which induce apoptosis. For example, etoposide and camptothecin are inhibitors of topoisomerases. As a consequence, DNA replication or DNA repair processes are blocked. Doxorubicin and daunorubicin are DNA intercalators. Doxorubicin has been reported to induce CD95 (Fas/Apo-1) gene expression in a p53-dependent mechanism in human primary endothelial cells. Moreover it has been shown to trigger apoptosis in various cell lines and its application in cancer treatment has revealed that p53 accumulates in cells exposed to doxorubicin.
- 5-FU is an antimetabolite drug widely used in treatment of colorectal cancer. 5-FU exerts its anticancer effects through inhibition of thymidylate synthase and incorporation of its metabolites into mRNA and DNA resulting in the blockage of their synthesis. Studies on 5FU have shown a clear role for p53 in cell culture, where the loss of p53 function reduces cellular sensitivity to 5-FU, and in vivo, where a number of clinical studies have found that mutant p53 over expression correlates with resistance to 5-FU. Typically, when 5-FU is administered to a patient, leucovorin is also administered since it enhances the activity of agents such as 5-FU.
- chemotherapeutic treatments can be an effective means to control disease.
- most chemotherapeutic treatments have undesirable side effects that cause the subject pain and suffering. It is therefore desirable to discover alternative treatment regimes that are more effective and result in a reduction in side effects either by shortening the treatment period or by using lower doses of chemotherapeutic agent.
- SIRT1 is regulated by post-translational modification.
- SIRT1 is variably phosphorylated at serine 27 (S27) and that S27P correlates with elevated SIRT1 protein levels in human cancer cells versus non- cancer cells, despite similar SIRT1 mRNA levels.
- S27 serine 27
- a combined therapeutic composition comprising: an inhibitor of JNK2 and at least one chemotherapeutic agent.
- JNK2 is encoded by a nucleic acid molecule comprising a nucleic acid sequence as shown in Figure 5a, 5b or 5c or a nucleic acid molecule that hybridizes under stringent hybridization conditions to the sequence shown Figure 5a, 5b or 5c and that encodes a polypeptide which has the activity of JNK2.
- JNK2 is encoded by a nucleic acid molecule as represented in Figure 5a, 5b or 5c.
- Hybridization of a nucleic acid molecule occurs when two complementary nucleic acid molecules undergo an amount of hydrogen bonding to each other.
- the stringency of hybridization can vary according to the environmental conditions surrounding the nucleic acids, the nature of the hybridization method, and the composition and length of the nucleic acid molecules used. Calculations regarding hybridization conditions required for attaining particular degrees of stringency are discussed in Sambrook et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001); and Tijssen, Laboratory Techniques in Biochemistry and Molecular Biology — Hybridization with Nucleic Acid Probes Part I, Chapter 2 (Elsevier, New York, 1993).
- the T m is the temperature at which 50% of a given strand of a nucleic acid molecule is hybridized to its complementary strand. The following is an exemplary set of hybridization conditions and is not limiting:
- Hybridization 5x SSC at 65°C for 16 hours
- Hybridization 5x-6x SSC at 65°C-70°C for 16-20 hours
- Hybridization 6x SSC at RT to 55 0 C for 16-20 hours
- nucleic acid molecule encodes a polypeptide as represented by the amino acid sequence as shown in Figure 6a, 6b or 6c.
- said inhibitor of JNK2 is a siRNA molecule derived from the nucleic acid sequence in Figure 5a, 5b or 5c.
- a technique to specifically ablate gene function is through the introduction of double stranded RNA, also referred to as small inhibitory or interfering RNA (siRNA), into a cell which results in the destruction of mRNA complementary to the sequence included in the siRNA molecule.
- the siRNA molecule comprises two complementary strands of RNA (a sense strand and an antisense strand) annealed to each other to form a double stranded RNA molecule.
- the siRNA molecule is typically derived from exons of the gene which is to be ablated. The mechanism of RNA interference is being elucidated.
- siRNAs proteins
- the siRNA acts as a guide for the RNase complex to cleave mRNA complementary to the antisense strand of the siRNA thereby resulting in destruction of the mRNA.
- WO2006125977 we disclose a modified siRNA-DNA construct (termed 'crook' siRNA). When transfected into mammalian cells crook siRNA induces selective mRNA knock-down equivalent to its unmodified siRNA counterpart. This bi-functional siRNA and the content of WO2006125977 are incorporated by reference in its entirety.
- said JNK2 siRNA is a hybrid nucleic acid molecule comprising a first part that comprises a duplex ribonucleic acid (RNA) molecule and a second part that comprises a single stranded deoxyribonucleic acid (DNA) molecule.
- RNA duplex ribonucleic acid
- DNA deoxyribonucleic acid
- said single stranded DNA molecule is contiguous with the sense strand of said duplex RNA molecule.
- said single stranded DNA molecule is contiguous with the antisense strand of said duplex RNA molecule.
- said single stranded DNA molecule is extended and is contiguous with both sense and antisense strands of said duplex RNA molecule.
- said single stranded DNA molecule comprises a 3' terminal nucleic acid sequence wherein said sequence is adapted over at least part of its length to anneal by complementary base pairing to a part of said single stranded DNA to form a double stranded DNA structure.
- said single stranded DNA molecule comprises at least one copy of the sequence d (GCGAAGC).
- the single stranded DNA molecule is at least 7 nucleotides in length.
- said single stranded DNA molecule is between 10-40 nucleotide bases in length, more preferably 15-30 nucleotides in length.
- duplex RNA molecule is at least 18 base pairs in length.
- said duplex RNA molecule is between 19bp and IOOObp in length. More preferably the length of said duplex RNA molecule is at least 30bp; at least 40bp; at least 50bp; at least 60bp; at least 70bp; at least ⁇ Obp; or at least 90bp.
- said duplex RNA molecule is at least 100bp; at least 200bp; at least 300bp; at least 400bp; at least 500bp; at least at least 600bp; at least 700bp; at least ⁇ OObp; at least 900bp; or at least IOOObp in length.
- duplex RNA molecule is between 18bp and 29bp in length. More preferably still said duplex RNA molecule is between 21 bp and 27bp in length. Preferably said duplex RNA molecule is about 21 bp in length.
- said inhibitor is a polypeptide or peptide; preferably a modified peptide inhibitor.
- said agent is a peptide or polypeptide.
- said peptide is at least 6 amino acid residues in length.
- the length of said peptide/polypeptide is selected from the group consisting of: at least 7 amino acid residues; 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues in length.
- the length of said peptide/polypeptide is at least 20 amino acid residues; 30; 40; 50; 60; 70; 80; 90; or 100 amino acid residues in length.
- modification to the amino acid sequence of peptide agents could enhance the binding and/or stability of the peptide with respect to its target sequence.
- modification of the peptide may also increase the in vivo stability of the peptide thereby reducing the effective amount of peptide necessary to inhibit JNK2. This would advantageously reduce undesirable side effects which may result in vivo.
- Modifications include, by example, acetylation and amidation.
- said modification includes the use of modified amino acids in the production of recombinant or synthetic forms of peptides.
- modified amino acids include, 4-hydroxyproline, 5-hydroxylysine, N 6 -acetyllysine, N 6 -methyllysine, N 6 ,N 6 -dimethyllysine, N 6 ,N 6 ,N 6 -trimethyllysine, cyclohexyalanine, D-amino acids, ornithine.
- Other modifications include amino acids with a C 2 , C 3 or C 4 alkyl R group optionally substituted by 1 , 2 or 3 substituents selected from halo ( eg F, Br, I), hydroxy or C 1 -C 4 alkoxy.
- Modifications also include, by example and not by way of limitation, acetylation and amidation of amino and carboxy-terminal amino acids.
- Cyclisation is known in the art, (see Scott et al Chem Biol (2001), 8:801- 815; Gellerman et al J. Peptide Res (2001), 57: 277-291; Dutta et al J. Peptide Res (2000), 8: 398-412; Ngoka and Gross J Amer Soc Mass Spec (1999), 10:360-363.
- said polypeptide is an antibody; preferably a monoclonal antibody or fragment thereof, that binds JNK2.
- a Fab fragment is a multimeric protein consisting of the immunologically active portions of an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, covalently coupled together and capable of specifically binding to an antigen.
- Fab fragments are generated via proteolytic cleavage (with, for example, papain) of an intact antibody molecule.
- a Fab 2 fragment comprises two joined Fab fragments. When these two fragments are joined by the immunoglobulin hinge region, a F(ab') 2 fragment results.
- An Fv fragment is multimeric protein consisting of the immunologically active portions of an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region covalently coupled together and capable of specifically binding to an antigen.
- a fragment could also be a single chain polypeptide containing only one light chain variable region, or a fragment thereof that contains the three Complementarity Determining Region (CDRs) of the light chain variable region, without an associated heavy chain variable region, or a fragment thereof containing the three CDRs of the heavy chain variable region, without an associated light chain moiety; and multi specific antibodies formed from antibody fragments, this has for example been described in US patent No 6,248,516.
- Fv fragments or single region (domain) fragments are typically generated by expression in host cell lines of the relevant identified regions.
- said chemotherapuetic agent is an anti- metabolic drug.
- said drug is a purine analogue. In an alternative preferred embodiment of the invention said drug is a pyrimidine analogue.
- Purine analogues are known in the art; for example thioguanine is used to treat acute leukaemia; fludarabine inhibits the function of DNA polymerases, DNA primases and
- DNA ligases and is specific for cell-cycle S-phase; pentostatin and cladribine are adenosine analogues and are effective against hairy cell leukaemias. Pyrimidine analogues are similarly known in the art.
- 5-fluorouracil 5-FU
- floxuridine floxuridine
- cytosine arabinoside 5-FU
- 5-FU has been used for many years in the treatment of breast, colorectal cancer, pancreatic and other cancers.
- 5-FU can also been formed from the pro-drug capecitabine which is converted to 5-FU in the tumour.
- said chemotherapeutic agent is 5- fluorouracil.
- said anti-metabolic drug is administered with leucovorin.
- Leucovorin also known as folinic acid
- folinic acid is administered as an adjuvant in cancer chemotherapy and which enhances the inhibitory effects of 5-FU on thymidylate synthase.
- compositions of the invention are administered in effective amounts.
- An "effective amount” is that amount of a composition that alone, or together with further doses, produces the desired response.
- the desired response is inhibiting the progression of the disease. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently. This can be monitored by routine methods.
- Such amounts will depend, of course, on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is generally preferred that a maximum dose of the individual components or combinations thereof be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.
- compositions used in the foregoing methods preferably are sterile and contain an effective amount of an inhibitor/agent according to the invention for producing the desired response in a unit of weight or volume suitable for administration to a patient.
- the response can, for example, be measured by determining regression of a tumour, decrease of disease symptoms, modulation of apoptosis, etc.
- the doses of the inhibitor/agent according to the invention administered to a subject can be chosen in accordance with different parameters, in particular in accordance with the mode of administration used and the state of the subject. Other factors include the desired period of treatment. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits.
- compositions for the administration of compositions
- administration of compositions to mammals other than humans is carried out under substantially the same conditions as described above.
- a subject as used herein, is a mammal, preferably a human, and including a non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent.
- the pharmaceutical preparations of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable compositions.
- pharmaceutically acceptable means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents.
- the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention.
- Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like.
- pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.
- compositions may be combined, if desired, with a pharmaceutically-acceptable carrier.
- pharmaceutically-acceptable carrier means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human.
- carrier in this context denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application, e.g. liposome or immuno-liposome.
- the components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.
- the pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.
- suitable buffering agents including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.
- suitable preservatives such as: benzalkonium chloride; chlorobutanol; parabe ⁇ s and thimerosal.
- compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.
- compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound.
- Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as syrup, elixir or an emulsion or as a gel.
- Compositions may be administered as aerosols and inhaled.
- compositions suitable for parenteral administration conveniently comprise a sterile aqueous or non-aqueous preparation of nucleic acid, which is preferably isotonic with the blood of the recipient.
- This preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation also may be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent, for example, as a solution in 1 , 3-butane diol.
- the acceptable solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono-or di-glycerides.
- fatty acids such as oleic acid may be used in the preparation of injectables.
- Carrier formulation suitable for oral, subcutaneous, intravenous, intramuscular, etc. administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA.
- a method to diagnosis a disease condition that is associated with the phosphorylation of a sirtuin polypeptide comprising: i) providing an isolated sample comprising a cell to be tested; ii) determining the phosphorylation of at least one amino acid residue in a sirtuin polypeptide; and iii) comparing the phosphorylation of said polypeptide in said sample to a control sample.
- sirtuin is SIRT1; preferably said sirtuin is represented by the amino acid sequence in Figure 7.
- said phosphorylation is at serine 27 as shown in Figure 7.
- said method includes a comparison of the phosphorylation of serine 27 with the phosphorylation of serine 47 in the amino acid sequence represented in Figure 7.
- the detection of phosphorylated amino acids is facilitated by the use of antibodies that specifically recognise phosophorylated serine residues; in particular specific antibodies that bind phosphorylated serine 27 and serine 47 in human SIRT1 are commercially available.
- said disease condition is a hyper-proliferative disease.
- said disease is a viral infection caused by a pathogenic virus.
- said disease is viral induced cancer.
- said disease is a viral induced cancer resulting form a human papilloma virus (HPV).
- HPV human papilloma virus
- HPV-6 and HPV-11 cause benign hyperplasia such as genital warts while high risk HPVs 1 for example HPV-16, HPV-18, HPV-31, HPV-33, HPV-52, HPV-54 and HPV-56 can cause cancers such as cervical and penile carcinoma.
- HPV-5 and HPV-8 cause malignant squamous cell carcinomas of the skin.
- HPV-2 is found in malignant and non-malignant lesions in cutaneous and squamous epithelium.
- said human papilloma virus is HPV-16 or HPV-18.
- viruses that have an association with cancer include, Polyomavirus which is associated with colorectal cancer; human herpesvirus-8 is associated with Karposi's sarcoma and Epstein Barr Virus associated with Burkitts lymphoma.
- RNA viruses are also associated with certain cancers, for example Human T cell leukaemia virus-1 and Hepatitis C virus.
- a yet further example is HIV and Kaposi's sarcoma
- said hyper-proliferative disease is cancer.
- cancer refers to cells having the capacity for autonomous growth, i.e., an abnormal state or condition characterized by rapidly proliferating cell growth.
- the term is meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness.
- cancer includes malignancies of the various organ systems, such as those affecting, for example, lung, breast, thyroid, lymphoid, gastrointestinal, and genito-urinary tract, as well as adenocarcinomas which include malignancies such as most colon cancers e.g.
- carcinoma is art recognized and refers to malignancies of epithelial or endocrine tissues including respiratory system carcinomas, gastrointestinal system carcinomas, genitourinary system carcinomas, testicular carcinomas, breast carcinomas, prostatic carcinomas, endocrine system carcinomas, and melanomas.
- exemplary carcinomas include those forming from tissue of the cervix, lung, prostate, breast, head and neck, colon and ovary.
- carcinosarcoma also includes carcinosarcomas, e.g., which include malignant tumours composed of carcinomatous and sarcomatous tissues.
- An "adenocarcinoma” refers to a carcinoma derived from glandular tissue or in which the tumour cells form recognizable glandular structures.
- the term “sarcoma” is art recognized and refers to malignant tumors of mesenchymal derivation.
- a method to diagnose and optionally treat a subject suffering from a condition which would benefit from the stimulation of apoptosis with a chemotherapeutic agent comprising the steps of: i) providing an isolated sample comprising a cell to be tested; ii) determining the phosphorylation of at least one amino acid residue in a polypeptide comprising an amino acid sequence as represented in Figure 7; iii) comparing the phosphorylation of said polypeptide in said sample to a control sample; and iv) identifying a chemotherapeutic treatment regime that would benefit said subject.
- said sample is additionally tested to determine the p53 genotype of said cell.
- said method includes the administration of at least one chemotherapeutic agent to said subject.
- said chemotherapeutic agent is 5-fluorouracil; preferably 5-fluorouracil is administered with an effective amount of thymidine.
- said phosphorylated amino acid residue is serine 27 in the amino acid sequence represented in Figure 7.
- said method includes a comparison of the phosphorylation state of serine 27 with the phosphorylation state of serine 47 in the amino acid sequence represented in Figure 7.
- said cell/tissue sample comprises pre-cancerous or cancerous cells.
- said pre-cancerous or cancerous tissue comprises transformed epithelial cells.
- said pre-cancerous or cancerous tissue is derived from the colon.
- Colorectal cancer is a cancer which occurs in the large intestine and rectum.
- the colon can be divided into effectively four sections; the ascending colon; the transverse colon; the descending colon; and the sigmoid colon.
- Most colorectal cancers arise in the sigmoid colon and develop from "polyps" which can grow for several years before becoming cancerous. The early detection of these pre-cancerous growths is obviously desirable since removal of the polyps is a very effective means to stem the progress of disease.
- colorectal cancer There are various types of colorectal cancer. Most cancers of this type are adenocarcinomas which are malignant growths which begin in the epithelial cells which line the colon and rectum.
- cancers of the colon and rectum include gastrointestinal stromal tumours and lymphomas.
- the patient can be asymptomatic and for this reason it is important that early screening is undertaken to identify those patients in which pre-cancerous polyps are forming.
- the chemotherapeutic agents typically used to treat colorectal cancer include 5-fluorouracil, leucovorin, irinotecan and capecitabine.
- said method further comprises the administration of a vector that includes a nucleic acid molecule that encodes a p53 polypeptide.
- nucleic acid molecules are part of an expression vector, preferably an expression vector adapted for eukaryotic gene expression.
- viruses or "viral vectors” as therapeutic agents is well known in the art. Additionally, a number of viruses are commonly used as vectors for the delivery of exogenous genes. Commonly employed vectors include recombinantly modified enveloped or non-enveloped DNA and RNA viruses, preferably selected from baculoviridiae, parvoviridiae, picornoviridiae, herpesveridiae, poxviridae, adenoviridiae, or picomnaviridiae. Chimeric vectors may also be employed which exploit advantageous elements of each of the parent vector properties (See e.g., Feng, et al.(1997) Nature Biotechnology 15:866-870).
- Such viral vectors may be wild-type or may be modified by recombinant DNA techniques to be replication deficient, conditionally replicating or replication competent.
- Preferred vectors are derived from the adenoviral, adeno-associated viral and retroviral genomes. In the most preferred practice of the invention, the vectors are derived from the human adenovirus genome. Particularly preferred vectors are derived from the human adenovirus serotypes 2 or 5.
- the replicative capacity of such vectors may be attenuated (to the point of being considered "replication deficient") by modifications or deletions in the E1a and/or E1b coding regions. Other modifications to the viral genome to achieve particular expression characteristics or permit repeat administration or lower immune response are preferred.
- the vector is replication deficient vector adenoviral vector encoding the p53 tumour suppressor gene A/C/N/53 as described in Gregory, et al., United States Patent No. 5,932,210 issued August 3, 1999 (the entire teaching of which is herein incorporated by reference).
- the viral vectors may be conditionally replicating or replication competent.
- Conditionally replicating viral vectors are used to achieve selective expression in particular cell types while avoiding untoward broad spectrum infection. Examples of conditionally replicating vectors are described in Pennisi, E. (1996) Science 274:342- 343; Russell, and S.J. (1994) Eur. J. of Cancer 30A(8):1165-1171. Additional examples of selectively replicating vectors include those vectors wherein a gene essential for replication of the virus is under control of a promoter which is active only in a particular cell type or cell state such that in the absence of expression of such gene, the virus will not replicate. Examples of such vectors are described in Henderson, et al., US 5,698,443; Henderson, et al., US 5,871,726 the entire teachings of which are herein incorporated by reference.
- the viral genome may be modified to include inducible promoters which achieve replication or expression only under certain conditions.
- inducible promoters are known in the scientific literature (see, Yoshida and Hamada (1997) Biochem. Biophys. Res. Comm. 230:426-430; lida, et al. (1996) J. Virol. 70(9):6054- 6059; Hwang, et al.(1997) J. Virol 71(9):7128-7131; Lee, et al. (1997) MoI. Cell. Biol. 17(9):5097-5105; and Dreher, et al.(1997) J. Biol. Chem 272(46); 29364-29371.
- the viruses may also be designed to be selectively replicating viruses. Particularly preferred selectively replicating viruses are described in Ramachandra, et al. PCT International Publication No. WO00/22137 International Application No. PCT/US99/21452 published April 20, 2000 and Howe, J., PCT International Publication No. WO WO0022136, International Application No. PCT/US99/21451 published April 20, 2000.
- viruses which are attenuated for replication are also useful in gene therapy.
- adenovirus dl1520 containing a specific deletion in the E1b55K gene has been used with therapeutic effect in human beings.
- Such vectors are also described in McCormick US 5,677,178 and US 5,846,945.
- vectors exhibit a natural tropism for certain tissue types.
- vectors derived from the genus herpesviridiae have been shown to have preferential infection of neuronal cells.
- examples of recombinantly modified herpesviridiae vectors are disclosed in US 5,328,688.
- Cell type specificity or cell type targeting may also be achieved in vectors derived from viruses having characteristically broad infection by the modification of the viral envelope proteins.
- cell targeting has been achieved with adenovirus vectors by selective modification of the viral genome knob and fibre coding sequences to achieve expression of modified knob and fibre domains having specific interaction with unique cell surface receptors.
- nucleic acid molecule encoding p53 is represented by the nucleic acid sequence presented in Figure 8.
- nucleic acid molecule encodes a p53 polypeptide as represented by the amino acid sequence in Figure 9.
- said subject is further administered an agent that inhibits the activity of the RNA-binding protein HuR.
- said agent is an antibody or fragment thereof.
- said agent is an siRNA; preferably said siRNA is derived from the nucleic acid sequence in Figure 10.
- nucleic acid molecule that encodes p53 is modified wherein said modification prevents or inhibits the binding of the RNA-binding protein HuR to the 5' and/or 3' leader sequences of p53 mRNA.
- said subject is administered an agent that inhibits the binding of the RNA-binding protein HuR to mRNA that encodes SIRT1.
- a method to screen for agents that modulate the activity of at least one sirtuin associated with the initiation and/or progression of cancer comprising the steps of: i) forming a preparation comprising at least one sirtuin polypeptide wherein said polypeptide is represented by the amino acid sequence in Figure 7, or a variant thereof, and at least one candidate agent to be tested; and ii) determining the activity of said agent with respect to activity of said polypeptide.
- said agent inhibits the phosphorylation of said polypeptide.
- polypeptide is represented by the amino acid sequence in Figure 7.
- said polypeptide is expressed by a cell wherein said cell is transformed or transfected with a nucleic acid molecule that encodes a sirtiun polypeptide.
- nucleic acid molecule is part of a vector adapted for recombinant expression of said nucleic acid molecule.
- said vector is provided with a promoter which enables the expression of said nucleic acid molecule to be regulated.
- said cell is derived from the colon, preferably said cell is an epithelial cell which lines the colon.
- Figure 1 illustrates cancer cells express elevated levels of SIRT1 protein and this correlates with SIRT1 S27 phosphorylation
- a Schematic of human sirtuins SIRT1-7 showing conserved catalytic domain (black bar) and unique N- and C-terminal domains.
- b SIRT1 N-terminal residues 16-55 with sites of phosphorylated serines 27 and 47 indicated
- c lmmunoblot showing SIRT1 protein levels, S27P and S47P between 15 human non-cancer (NC) and cancer (C) cell lines
- NC non-cancer
- C cancer
- Figure 2 illustrates 5-FU induces rapid loss of SIRT1 mRNA associated with p53- dependent decrease in total SIRT1 protein in ARPE-19 and HCT ⁇ 16 cells
- a Levels of SIRT1, laminA/C and GAPDH mRNAs determined by qRT-PCR at 24h 5-FU exposure.
- b SIRT1 mRNA levels at Oh, 2h, 6h, 12h and 24h after treatment with 5-FU.
- d Protein levels of total SIRT1 , SIRT1 S27P, SIRT1 S47P, p53 and p53 K382Ac at Oh, 2h, 6h, 12h and 24h after treatment with 5-FU.
- Figure 3 illustrates that in cancer cells the maintenance of SIRT1 protein and phosphorylation levels is dependent upon JNK2 and p53.
- a SIRT1, JNK1 and JNK2 protein levels and
- b mRNA levels in ARPE-19 cells at 24h, 48h, 72h and 96h post- transfection with SIRT1 siRNA, JNK2 siRNA or JNK1 siRNA as indicated, c-e.
- Figure 4 illustrates a schematic summarising SIRT1 phosphorylation in non-cancer and cancer cells, and the effects of 5FU and/or JNK2 silencing;
- Figure 5a is the nucleic acid sequence of human JNK2 variant 1;
- Figure 5b is the nucleic acid sequence of human JNK2 variant 2;
- Figure 5c is the nucleic acid sequence of human JNK2 variant 4;
- Figure 6a is the amino acid sequence of human JNK2 variant 1 ;
- Figure 6b is the amino acid sequence of human JNK2 variant 2;
- Figure 6c is the amino acid sequence of human JNK2 variant 4;
- Figure 7a is the nucleic acid sequence of human SIRT1 ;
- Figure 7b is the amino acid sequence of human SIRT1;
- Figure 8 is the nucleic acid sequence of human p53;
- Figure 9 is the amino acid sequence of human p53
- Figure 10a is the nucleic acid sequence of the RNA-binding protein HuR;
- Figure 10b is the amino acid sequence of RNA-binding protein HuR;
- Figure 11 is a western blot showing expression in human keratinocytes tranfected with expression vectors for HPV16 E6 and HPV16 E7 oncogenes and that E7 induces differential phosphorylation of SIRTi;
- Figure 12 Phenotype of enforced expression of HPV-16 viral transcripts in NHEK cells. a. Digital phase contrast images of NHEK cells at 48 hours post-transfection with E6 or E7 viral transcript expression vectors, b. Colony forming assay of NHEK transfected with E6 or E7 expression vectors; and
- FIG. 13 JNK-dependent phosphorylation at S27 stabilises exogenous SIRT1 protein.
- a Schematic of experimental protocol for RNAi followed by transfection with exogenous SIRT1 expression vector (see text)
- b Exogenous expression of SIRT1 in intact HCT116 ceils (lane 2), JNK2-depleted cells (lane 3) and JNK1-depleted cells (lane 4) detected by immunoblotting.
- Lane 1 intact, non-transfected cells. Note that in both intact cells and JNK1 -depleted cells the exogenous SIRT1 is phosphorylated on S27 and S47, whereas in JNK2-depleted cells S27P levels reflect endogenous SIRT1 (lanes 1 and 3, asterix), c, d.
- Epithelial cancer cell lines RKO, LoVo, DLD-1, HT29, U2OS, SAOS-2, MCF7, HTB-126, HT-1080 and SiHa were obtained from ATCC.
- Isogenic colorectal carcinoma cell lines HCT116 p53+/+ and HCT116 p53-/- were a kind gift of Bert Vogelstein.
- Non-cancer cells were normal diploid fibroblasts (NDF) and ARPE-19 immortalised retinal epithelial cells (ATCC), and normal human embryonic keratinocytes (NHEK, Invitrogen). Cells were cultured according to the supplier's protocols. siRNA sequences, transfection protocols and target validations were as described (Ref. 27 and Methods).
- cells were treated 48 hours post-plating with final concentration of 5-FU (375 GM) and uridine (425 DM) as indicated and harvested 24h later.
- 5-FU 375 GM
- uridine 425 DM
- drugs were applied 24h post-transfection and cells harvested 24h later.
- time course analyses cells were harvested at indicated time points post-treatment.
- Cellular mRNAs were extracted for quantitative RT-PCR as previously described 27 . Primers and thermal cycling conditions were as described 27 (Methods); quantifications were performed in triplicate.
- Antibodies were: Anti- SIRT1 (H-300, Santa Cruz), anti-phosphoserine27-SIRT1 (#2327, Cell Signaling), anti- phosphoserine47-SIRT1 (#2314, Cell Signaling), anti-actin (MAB1501, Chemicon), anti- p53 (DO-1, Santa Cruz), anti-acetylated-p53-lysine382 (#2525, Cell Signaling), anti- JNK1 (F-3, Santa Cruz), anti-JNK2 (#4672, Cell Signaling). Visualisation of bound antibodies was by ECL, with quantitation by densitometry of signals within the linear range.
- Phase contrast digital images were captured using an Axiovert 200M microscope (Zeiss). Apoptotic cells were identified by flow cytometry using annexin-V-Fluos (Roche) following the manufacturer's protocol.
- Colorectal carcinoma cell lines HCT116 (p53+/+ and isogenic p53-/-), LoVo (p53 wild-type) and HT29 (p53 mutant) were cultured in DMEM (Gibco); colorectal carcinoma cell line DLD-1 (p53 mutant) was cultured in RPMI
- JNK1 siRNA sequences were: Sense 5'-CUCCACCACCAAAGAUCCC(dTdT)-3 I 1 antisense 5'-GGGAUCUUUGGUGGUGGAG(dTdT)-3'.
- JNK2 siRNA sequences were: Sense 5'-GAGCUGGUGAAAGGUUGUG(dTdT)-3', antisense 5'-CACAACCUUU CACCAGCUC(dTdT)-3'.
- Specificities of SIRT1 siRNA, JNK1 siRNA and JNK2 siRNA have been validated previously 27 (Ahmed and Milner, in submission). Cells were harvested for analysis 48h post-transfection, except where indicated otherwise.
- drugs were applied by complete media replacement 48h post-plating at final concentration 375 ⁇ M (5-FU) or 425 ⁇ M (uridine). Cells were harvested for analysis 24h following application of drugs, or at the indicated timepoints for time-course analysis. For combined transfection/drug experiments, drugs were applied approximately 20 hours post-transfection. Cells from combined transfection/drug experiments were harvested for analysis after 24 hours of drug exposure ( ⁇ 48 hours post-transfection).
- cell counts or protein assay was performed, with the method chosen consistent within each experiment.
- Cells were lysed in lysis buffer IPAMN (10 mM TRIS base pH 8.0, 140 mM NaCI, 2 mM CaCI 2 , 0.5% NP-40, 5 U ml "1 micrococcal nuclease) for 3 minutes at room temperature followed by addition of 0.25x volumes of 6x SDS-PAGE sample buffer and brief heating to 90 0 C.
- Samples for protein assay were withdrawn before addition of 6x SDS-PAGE sample buffer, and assayed using BCA Protein Assay Kit (Pierce) according to the manufacturer's instructions.
- Antibodies were: Anti-SIRT1 (H-300, Santa Cruz), anti-phosphserine27-SIRT1 (#2327, Cell Signaling), anti-phosphoserine47-SIRT1 (#2314, Cell Signaling), anti-actin (MAB1501 , Chemicon), anti-p53 (DO-1, Santa Cruz), anti-acetylated-p53-lysine382 (#2525, Cell Signaling), anti-JNK1 (F-3, Santa Cruz), anti- JNK2 (#4672, Cell Signaling). Bound antibodies were visualised by ECL (Roche). Densitometry was performed from under-exposed images within the linear range, using Quantity One analysis software (BioRad).
- Relative mRNA levels were quantitated by realtime RT-PCR. Primer sequences and thermal cycles for GAPDH and LaminA/C have been described previously 27 .
- SIRT1 primers ⁇ '-CTAATTCCAAGTTCCATACCC-S' and 5'-CTGAAGAATCTGGTGGTGAAG-3 I were used in the thermal cycle: 5O 0 C for 30 minutes, 94 0 C for 15 minutes, followed by 35 cycles of 94 0 C for 30 seconds, 55 0 C for 30 seconds, 72 0 C for 30 seconds, then 75 0 C for 15 seconds before the plate was read.
- JNK1 primers 5'- CCAGGAAGGGACTATATTGATC-3' and ⁇ '-TCTCTCCTCCAAGTCCATAACT-S' were used in the thermal cycle: 50 0 C for 30 minutes, 94 0 C for 15 minutes, followed by 35 cycles of 94 0 C for 30 seconds, 57 0 C for 30 seconds, 72 0 C for 30 seconds, then 75 0 C for 15 seconds before the plate was read.
- JNK2 primers 5'-GAAGCCTAGCAACATTGTTG- 3' and 5'-GATCAATATGGTCAGTGCCT-3 I were used in the thermal cycle: 5O 0 C for 30 minutes, 94 0 C for 15 minutes, followed by 35 cycles of 94 0 C for 30 seconds, 55 0 C for 30 seconds, 72 0 C for 30 seconds, then 75 0 C for 15 seconds before the plate was read. All RT-PCR quantifications were performed in triplicate.
- SIRT1 is subject to post-translational regulation.
- Putative phosphorylation sites at S27 and S47 within the unique SIRT1 N-terminal domain (Fig. 1a and b) have previously been revealed by mass spectrometry 23 .
- Methods To investigate the significance of these sites we screened a series of human cell lines using commercially available antisera raised against synthetic SIRT1 S27P and S47P phosphopeptides (Methods).
- SIRT1 knock-down by RNA interference (RNAi) showed equivalent knockdown of S27P and S47P in HCT116 cells, thus validating anti-SIRT1 activity of the anti- phosphopeptide antisera (Fig. 1c).
- RNAi RNA interference
- SIRT1 S27P Under basal conditions of culture SIRT1 S27P appeared restricted to cancer cells, being undetectable in non-cancer ARPE-19 epithelial cells, primary human keratinocytes
- SIRT1 S47P was evident in both non-cancer and cancer cell lines (with the exception of primary human epidermal keratinocytes in which S47P was undetectable; Fig. 1c).
- SIRT1 S47P levels tended to parallel total SIRT1 protein (SIRT1:S47P ratio range 0.8 to 1.5, as determined by gel scanning, see Methods) suggesting constitutive phosphorylation at this site.
- SIRT1:S47P ratio range 0.8 to 1.5 as determined by gel scanning, see Methods suggesting constitutive phosphorylation at this site.
- SIRT1:S27P ratio range 3.4 to 34).
- the observed variability in S27 phosphorylation relative to total SIRT1 protein indicates that S27 phosphorylation is subject to cellular regulation.
- Total SIRT1 protein levels were generally high in cancer relative to non-cancer cells (Fig.1c; see also below). The one exception was HT29 colorectal cancer cells which expressed low levels of total SIRT1. The HT29 cells also differed from the remaining cancer cell lines in that SIRT1 was un-phosphorylated on S27 (Fig. 1c).
- S27P is variable relative to total SIRT1 and correlates with the elevated SIRT1 protein levels observed in cancer cells under basal conditions of growth.
- SIRT 1 protein levels in non-cancer versus cancer cell lines employed ARPE-19 cells (spontaneously immortalised human retinal epithelial cells of non-cancerous origin) and HCT116 p53+/+ and p53-/- isogenic human colorectal cancer epithelial cells 24 .
- Comparison of SIRT1 protein levels on a per cell basis revealed -15 to 20-fold higher SIRT1 levels in HCT116 cells compared with ARPE-19 cells (Fig. 1d, 1e & 1f).
- SIRT1 mRNA levels were similar in both ARPE-19, HCT116 p53+/+ and HCT116 p53-/- cells (Fig. 1g).
- SIRT1 protein levels were not attributable to differences in gene expression levels or mRNA stability. They may therefore reflect differences in the efficiency of mRNA translation and/or SIRT1 protein stability.
- SIRT1 is not thought to be regulated via variable translation efficiency, our results indicate that high SIRT1 protein levels in human cancer cells reflect abnormally increased protein stability. Since SIRT1 protein stability shows a positive correlation with phosphorylation at S27 it is possible that S27P prolongs the half-life of cellular SIRT1 protein.
- 5-FU induces any changes in SIRT1 levels and/or phosphorylation status.
- 5-FU is a clinically important anti-cancer drug and is the treatment of choice for colorectal cancer.
- the mechanism of action of 5-FU is complex and includes perturbation of DNA synthesis culminating in DNA damage, and also incorporation into newly synthesised RNAs with consequential inhibition of RNA processing 25 ' 26 .
- treatment of cells with 5-FU for 24h resulted in 80% depletion of SIRT1 mRNA, whilst lamin A/C and GAPDH mRNA levels were relatively unaffected (Fig. 2a).
- HCT116 p53+/+ colorectal cancer cells displayed a sustained p53 response to 5-FU and this correlated with induction of p53 K382 acetylation and apoptosis (Fig. 2c centre panel and 2d, 2e). Similar differences between normal and cancerous cells may contribute to the preferential anti-cancer effects of 5-FU in the clinic.
- RNA interference results in reduced levels of SIRT1 protein (Ahmed and Milner, unpublished observations and Fig. 3a centre panel).
- This unexpected effect was attributed to decreased SIRT1 protein stability since SIRT1 mRNA levels remained constant (Fig. 3a and b, centre panels).
- the effect was specific to JNK2 since JNK1 silencing had no effect upon SIRT1 protein levels (Fig 3a and b, right hand panels). Also there was no reciprocal effect of SIRT1 silencing on JNK2 protein levels (Fig. 3a, left hand panel).
- the JNK2 kinase may, directly or indirectly, influence SIRT1 protein stability and that such an effect may operate via SIRT1 phosphorylation.
- Figure 11 illustrates expression levels and phosphorylation status of SIRT1 protein in primary human keratinocytes following expression of vectors encoding HPV16 E6 and
- HPV16 E7 oncoproteins HPV16 E7 oncoproteins. Cells were transfected with expression vectors and analysed
- Vaziri, H. et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Ce// 107, 149-159 (2001).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
This disclosure relates to a SIRT1 polypeptide and a treatment regime that inhibits the activity of SIRT1 and including a method of diagnosis.
Description
Combination Therapy
The invention relates to a treatment regime suitable to control the activity of a sirtuin, for example SIRT1, typically in the treatment of hyperproliferative diseases such as cancer; and including diagnostic tests that detects differential phosphorylation of sirtuin polypeptides.
Apoptosis is a process by which multi-cellular organisms regulate cell number and differentiation. The process is regulated by factors which either induce or prevent apoptosis. Tumour suppressor proteins have pro-apoptotic activities. Tumour suppressor genes encode proteins which function to inhibit cell growth or division and are therefore important with respect to maintaining proliferation, growth and differentiation of normal cells. Mutations in tumour suppressor genes result in abnormal cell-cycle progression whereby the normal cell-cycle check points which arrest the cell- cycle, when, for example, DNA is damaged, are ignored and damaged cells divide uncontrollably. The products of tumour suppressor genes function in all parts of the cell (e.g. cell surface, cytoplasm, mitochondrion and nucleus) and prevent the passage of damaged cells through the cell- cycle.
Arguably the tumour suppressor gene which has been the subject of the most intense research is p53. p53 encodes a protein which functions as a transcription factor and is a key regulator of the cell division cycle. It was discovered in 1978 as a protein shown to bind with affinity to the SV40 large T antigen. The p53 gene encodes a 393 amino acid polypeptide with a molecular weight of 53kDa. Genes regulated by the transcriptional activity of p53 contain a p53 recognition sequence in their 5' regions. These genes are activated when the cellular levels of p53 are elevated due to, for example, DNA damage. Examples of genes that respond to p53 include, mdm2, Bax and PIG-3. Bax and PIG-3 are involved in one of the most important functions of p53, the induction of apoptosis.
The ability of mammalian cells to withstand metabolic and genotoxic stress involves SIRT1, a class III histone de-acetylase able to regulate gene expression at several levels. Thus deacetylation of linker histone H1 by SIRT1 enables heterochromatin formation and associated gene silencing16. SIRT1 also deacetylates core histone H3 and recruitment of SIRT1 to specific promoters results in selective gene silencing17'18. In
addition SIRT1 targets several non-histone transcription regulators including the tumour suppressor p5319'20. De-acetylation of p53 by SIRT1 down-regulates the pro-apoptotic p53 stress response11. SIRT1 and p53 thus counterbalance the cellular response to stress. This balance is dependent upon cellular levels of SIRT1 and p53 since over- expression favours cell survival or apoptosis respectively. Expression levels of p53 and SIRT1 therefore require stringent control. For p53 this is largely achieved through regulation of p53 protein stability21'22. For SIRT1 a transcriptional feed-back mechanism operates in which SIRT1 forms a complex with the transcription repressor hypermethylated in cancer 1 (HIC1) and selectively suppresses transcription from the SIRT1 promoter12'13. SIRT1 expression is also regulated at the level of mRNA stability via the RNA-binding protein HuR which binds and stabilises SIRT1 mRNA14'15.
In a large part the control of cell-cycle progression in eukaryotic cells is controlled by phosphorylation and de-phosphorylation of key regulators by kinases and phophatases respectively.
In mammals there are three families of Mitogen Activated Protein Kinase (MAPK). One family member is the c-jun NH2-terminal kinases (JNK). In humans there are three JNK kinases encoded by three genes; JNK1, JNK2 and JNK3. The JNK kinases exist in separate isoforms which are created by alternative splicing from mRNA. JNK1 produces four isoforms; JNK2 also produces four isoforms; and JNK3 produces 2 isoforms. The different JNK isoforms differ in the protein substrates that they modify. Inhibitors of JNK are well known in the art. For example, WO2005/074921 , which is incorporated by reference in its entirety, describes a pyrazolanthone inhibitor of JNK2 and its use in the treatment of atherosclerosis. Moreover there are commercially available JNK inhibitors specific to each JNK kinase; for example see Calbiochem kinase inhibitors at http://www.emdbiosciences.com/html/CBC/home.html: in particular for JNK2 specific inhibitors see Bennett et al 2001 Proc Natl Acad Sci USA 98, p13681; Han et a/ 2001, J Clin. Invest 108, p73; Shin et al 2002 Biochim Biophys. Acta, 1589, p311; which are incorporated by reference in their entirety.
Chemotherapeutic agents are generally more effective at killing cancer cells than normal cells. Examples of these agents are well known in the art, some of which induce apoptosis. For example, etoposide and camptothecin are inhibitors of topoisomerases. As a consequence, DNA replication or DNA repair processes are blocked. Doxorubicin and daunorubicin are DNA intercalators. Doxorubicin has been reported to induce CD95
(Fas/Apo-1) gene expression in a p53-dependent mechanism in human primary endothelial cells. Moreover it has been shown to trigger apoptosis in various cell lines and its application in cancer treatment has revealed that p53 accumulates in cells exposed to doxorubicin.
A further example of a chemotherapeutic agent is 5'Fluorouracil (5-FU). 5-FU is an antimetabolite drug widely used in treatment of colorectal cancer. 5-FU exerts its anticancer effects through inhibition of thymidylate synthase and incorporation of its metabolites into mRNA and DNA resulting in the blockage of their synthesis. Studies on 5FU have shown a clear role for p53 in cell culture, where the loss of p53 function reduces cellular sensitivity to 5-FU, and in vivo, where a number of clinical studies have found that mutant p53 over expression correlates with resistance to 5-FU. Typically, when 5-FU is administered to a patient, leucovorin is also administered since it enhances the activity of agents such as 5-FU.
The treatment of cancers using chemotherapy can be an effective means to control disease. However, most chemotherapeutic treatments have undesirable side effects that cause the subject pain and suffering. It is therefore desirable to discover alternative treatment regimes that are more effective and result in a reduction in side effects either by shortening the treatment period or by using lower doses of chemotherapeutic agent.
This disclosure relates to evidence that SIRT1 is regulated by post-translational modification. We show that SIRT1 is variably phosphorylated at serine 27 (S27) and that S27P correlates with elevated SIRT1 protein levels in human cancer cells versus non- cancer cells, despite similar SIRT1 mRNA levels. We also disclose the synergistic effect of combining an inhibitor of JNK2 with a chemotherapeutic agent such as 5-FU.
According to an aspect of the invention there is provided a combined therapeutic composition comprising: an inhibitor of JNK2 and at least one chemotherapeutic agent.
In a preferred embodiment of the invention JNK2 is encoded by a nucleic acid molecule comprising a nucleic acid sequence as shown in Figure 5a, 5b or 5c or a nucleic acid molecule that hybridizes under stringent hybridization conditions to the sequence shown Figure 5a, 5b or 5c and that encodes a polypeptide which has the activity of JNK2.
In a preferred embodiment of the invention JNK2 is encoded by a nucleic acid molecule as represented in Figure 5a, 5b or 5c.
Hybridization of a nucleic acid molecule occurs when two complementary nucleic acid molecules undergo an amount of hydrogen bonding to each other. The stringency of hybridization can vary according to the environmental conditions surrounding the nucleic acids, the nature of the hybridization method, and the composition and length of the nucleic acid molecules used. Calculations regarding hybridization conditions required for attaining particular degrees of stringency are discussed in Sambrook et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001); and Tijssen, Laboratory Techniques in Biochemistry and Molecular Biology — Hybridization with Nucleic Acid Probes Part I, Chapter 2 (Elsevier, New York, 1993). The Tm is the temperature at which 50% of a given strand of a nucleic acid molecule is hybridized to its complementary strand. The following is an exemplary set of hybridization conditions and is not limiting:
Very High Stringency (allows sequences that share at least 90% identity to hybridize) Hybridization: 5x SSC at 65°C for 16 hours
Wash twice: 2x SSC at room temperature (RT) for 15 minutes each Wash twice: 0.5x SSC at 65°C for 20 minutes each
High Stringency (allows sequences that share at least 80% identity to hybridize) Hybridization: 5x-6x SSC at 65°C-70°C for 16-20 hours
Wash twice: 2x SSC at RT for 5-20 minutes each Wash twice: 1 x SSC at 55°C-70°C for 30 minutes each
Low Stringency (allows sequences that share at least 50% identity to hybridize) Hybridization: 6x SSC at RT to 550C for 16-20 hours
Wash at least twice: 2x-3x SSC at RT to 55°C for 20-30 minutes each.
In a preferred embodiment of the invention said nucleic acid molecule encodes a polypeptide as represented by the amino acid sequence as shown in Figure 6a, 6b or 6c.
In a preferred embodiment of the invention said inhibitor of JNK2 is a siRNA molecule derived from the nucleic acid sequence in Figure 5a, 5b or 5c.
A technique to specifically ablate gene function is through the introduction of double stranded RNA, also referred to as small inhibitory or interfering RNA (siRNA), into a cell which results in the destruction of mRNA complementary to the sequence included in the siRNA molecule. The siRNA molecule comprises two complementary strands of RNA (a sense strand and an antisense strand) annealed to each other to form a double stranded RNA molecule. The siRNA molecule is typically derived from exons of the gene which is to be ablated. The mechanism of RNA interference is being elucidated. Many organisms respond to the presence of double stranded RNA by activating a cascade that leads to the formation of siRNA. The presence of double stranded RNA activates a protein complex comprising RNase III which processes the double stranded RNA into smaller fragments (siRNAs, approximately 21-29 nucleotides in length) which become part of a ribonucleoprotein complex. The siRNA acts as a guide for the RNase complex to cleave mRNA complementary to the antisense strand of the siRNA thereby resulting in destruction of the mRNA. In our co-pending application WO2006125977 we disclose a modified siRNA-DNA construct (termed 'crook' siRNA). When transfected into mammalian cells crook siRNA induces selective mRNA knock-down equivalent to its unmodified siRNA counterpart. This bi-functional siRNA and the content of WO2006125977 are incorporated by reference in its entirety.
In a preferred embodiment of the invention said JNK2 siRNA is a hybrid nucleic acid molecule comprising a first part that comprises a duplex ribonucleic acid (RNA) molecule and a second part that comprises a single stranded deoxyribonucleic acid (DNA) molecule.
In a preferred embodiment of the invention said single stranded DNA molecule is contiguous with the sense strand of said duplex RNA molecule.
In an alternative preferred embodiment of the invention said single stranded DNA molecule is contiguous with the antisense strand of said duplex RNA molecule.
In a preferred embodiment of the invention said single stranded DNA molecule is extended and is contiguous with both sense and antisense strands of said duplex RNA molecule.
In a preferred embodiment of the invention said single stranded DNA molecule comprises a 3' terminal nucleic acid sequence wherein said sequence is adapted over at
least part of its length to anneal by complementary base pairing to a part of said single stranded DNA to form a double stranded DNA structure.
In a preferred embodiment of the invention said single stranded DNA molecule comprises at least one copy of the sequence d (GCGAAGC).
Typically the single stranded DNA molecule is at least 7 nucleotides in length. Preferably said single stranded DNA molecule is between 10-40 nucleotide bases in length, more preferably 15-30 nucleotides in length.
In a preferred embodiment of the invention said duplex RNA molecule is at least 18 base pairs in length.
In a further preferred embodiment of the invention said duplex RNA molecule is between 19bp and IOOObp in length. More preferably the length of said duplex RNA molecule is at least 30bp; at least 40bp; at least 50bp; at least 60bp; at least 70bp; at least δObp; or at least 90bp.
In a yet further preferred embodiment of the invention said duplex RNA molecule is at least 100bp; at least 200bp; at least 300bp; at least 400bp; at least 500bp; at least at least 600bp; at least 700bp; at least δOObp; at least 900bp; or at least IOOObp in length.
Preferably said duplex RNA molecule is between 18bp and 29bp in length. More preferably still said duplex RNA molecule is between 21 bp and 27bp in length. Preferably said duplex RNA molecule is about 21 bp in length.
In an alternative preferred embodiment of the invention said inhibitor is a polypeptide or peptide; preferably a modified peptide inhibitor.
In a preferred method of the invention said agent is a peptide or polypeptide.
In a preferred method of the invention said peptide is at least 6 amino acid residues in length. Preferably the length of said peptide/polypeptide is selected from the group consisting of: at least 7 amino acid residues; 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues in length. Alternatively the length of said peptide/polypeptide
is at least 20 amino acid residues; 30; 40; 50; 60; 70; 80; 90; or 100 amino acid residues in length.
It will be apparent to one skilled in the art that modification to the amino acid sequence of peptide agents could enhance the binding and/or stability of the peptide with respect to its target sequence. In addition, modification of the peptide may also increase the in vivo stability of the peptide thereby reducing the effective amount of peptide necessary to inhibit JNK2. This would advantageously reduce undesirable side effects which may result in vivo. Modifications include, by example, acetylation and amidation. Alternatively or preferably, said modification includes the use of modified amino acids in the production of recombinant or synthetic forms of peptides. It will be apparent to one skilled in the art that modified amino acids include, 4-hydroxyproline, 5-hydroxylysine, N6-acetyllysine, N6-methyllysine, N6,N6-dimethyllysine, N6,N6,N6-trimethyllysine, cyclohexyalanine, D-amino acids, ornithine. Other modifications include amino acids with a C2, C3 or C4 alkyl R group optionally substituted by 1 , 2 or 3 substituents selected from halo ( eg F, Br, I), hydroxy or C1-C4 alkoxy. Modifications also include, by example and not by way of limitation, acetylation and amidation of amino and carboxy-terminal amino acids.
It will also be apparent to one skilled in the art that peptides could be modified by cyclisation. Cyclisation is known in the art, (see Scott et al Chem Biol (2001), 8:801- 815; Gellerman et al J. Peptide Res (2001), 57: 277-291; Dutta et al J. Peptide Res (2000), 8: 398-412; Ngoka and Gross J Amer Soc Mass Spec (1999), 10:360-363.
In a preferred embodiment of the invention said polypeptide is an antibody; preferably a monoclonal antibody or fragment thereof, that binds JNK2.
Various fragments antibodies are known in the art, (i.e., Fab, Fab2, F(ab')2, Fv, Fc, Fd, scFvs). A Fab fragment is a multimeric protein consisting of the immunologically active portions of an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, covalently coupled together and capable of specifically binding to an antigen. Fab fragments are generated via proteolytic cleavage (with, for example, papain) of an intact antibody molecule. A Fab2 fragment comprises two joined Fab fragments. When these two fragments are joined by the immunoglobulin hinge region, a F(ab')2 fragment results. An Fv fragment is multimeric protein consisting of the immunologically active portions of an immunoglobulin heavy chain variable region and
an immunoglobulin light chain variable region covalently coupled together and capable of specifically binding to an antigen.
A fragment could also be a single chain polypeptide containing only one light chain variable region, or a fragment thereof that contains the three Complementarity Determining Region (CDRs) of the light chain variable region, without an associated heavy chain variable region, or a fragment thereof containing the three CDRs of the heavy chain variable region, without an associated light chain moiety; and multi specific antibodies formed from antibody fragments, this has for example been described in US patent No 6,248,516. Fv fragments or single region (domain) fragments are typically generated by expression in host cell lines of the relevant identified regions. These and other immunoglobulin or antibody fragments are within the scope of the invention and are described in standard immunology textbooks. Molecular biology now allows direct synthesis (via expression in cells or chemically) of these fragments, as well as synthesis of combinations thereof. A fragment of an antibody or immunoglobulin can also have bispecific function.
In a preferred embodiment of the invention said chemotherapuetic agent is an anti- metabolic drug.
In a preferred embodiment of the invention said drug is a purine analogue. In an alternative preferred embodiment of the invention said drug is a pyrimidine analogue.
Purine analogues are known in the art; for example thioguanine is used to treat acute leukaemia; fludarabine inhibits the function of DNA polymerases, DNA primases and
DNA ligases and is specific for cell-cycle S-phase; pentostatin and cladribine are adenosine analogues and are effective against hairy cell leukaemias. Pyrimidine analogues are similarly known in the art. For example, 5-fluorouracil (5-FU), floxuridine and cytosine arabinoside. 5-FU has been used for many years in the treatment of breast, colorectal cancer, pancreatic and other cancers. 5-FU can also been formed from the pro-drug capecitabine which is converted to 5-FU in the tumour.
In a preferred embodiment of the invention said chemotherapeutic agent is 5- fluorouracil.
In a preferred embodiment of the invention said anti-metabolic drug is administered with leucovorin.
Leucovorin, also known as folinic acid, is administered as an adjuvant in cancer chemotherapy and which enhances the inhibitory effects of 5-FU on thymidylate synthase.
The compositions of the invention are administered in effective amounts. An "effective amount" is that amount of a composition that alone, or together with further doses, produces the desired response. In the case of treating a particular disease, such as cancer, the desired response is inhibiting the progression of the disease. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently. This can be monitored by routine methods.
Such amounts will depend, of course, on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is generally preferred that a maximum dose of the individual components or combinations thereof be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.
The pharmaceutical compositions used in the foregoing methods preferably are sterile and contain an effective amount of an inhibitor/agent according to the invention for producing the desired response in a unit of weight or volume suitable for administration to a patient. The response can, for example, be measured by determining regression of a tumour, decrease of disease symptoms, modulation of apoptosis, etc.
The doses of the inhibitor/agent according to the invention administered to a subject can be chosen in accordance with different parameters, in particular in accordance with the mode of administration used and the state of the subject. Other factors include the
desired period of treatment. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits.
Other protocols for the administration of compositions will be known to one of ordinary skill in the art, in which the dose amount, schedule of injections, sites of injections, mode of administration (e.g., intra-tumour) and the like vary from the foregoing. The administration of compositions to mammals other than humans, (e.g. for testing purposes or veterinary therapeutic purposes), is carried out under substantially the same conditions as described above. A subject, as used herein, is a mammal, preferably a human, and including a non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent.
When administered, the pharmaceutical preparations of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable compositions.
The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like. Also, pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.
Compositions may be combined, if desired, with a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" in this context denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application, e.g. liposome or immuno-liposome. The components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction
which would substantially impair the desired pharmaceutical efficacy.
The pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt. The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabeπs and thimerosal.
The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.
Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as syrup, elixir or an emulsion or as a gel. Compositions may be administered as aerosols and inhaled.
Compositions suitable for parenteral administration conveniently comprise a sterile aqueous or non-aqueous preparation of nucleic acid, which is preferably isotonic with the blood of the recipient. This preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent, for example, as a solution in 1 , 3-butane diol. Among the acceptable solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulation suitable for oral, subcutaneous, intravenous, intramuscular, etc. administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA.
According to a further aspect of the invention there is provided a method to diagnosis a
disease condition that is associated with the phosphorylation of a sirtuin polypeptide comprising: i) providing an isolated sample comprising a cell to be tested; ii) determining the phosphorylation of at least one amino acid residue in a sirtuin polypeptide; and iii) comparing the phosphorylation of said polypeptide in said sample to a control sample.
In a preferred method of the invention said sirtuin is SIRT1; preferably said sirtuin is represented by the amino acid sequence in Figure 7.
In a preferred embodiment of the invention said phosphorylation is at serine 27 as shown in Figure 7.
In a further preferred method of the invention said method includes a comparison of the phosphorylation of serine 27 with the phosphorylation of serine 47 in the amino acid sequence represented in Figure 7.
The detection of phosphorylated amino acids is facilitated by the use of antibodies that specifically recognise phosophorylated serine residues; in particular specific antibodies that bind phosphorylated serine 27 and serine 47 in human SIRT1 are commercially available.
In a preferred method of the invention said disease condition is a hyper-proliferative disease.
In a preferred method of the invention said disease is a viral infection caused by a pathogenic virus.
In a preferred method of the invention said disease is viral induced cancer.
In a preferred method of the invention said disease is a viral induced cancer resulting form a human papilloma virus (HPV).
Human papilloma viruses vary in their pathological effects. For example, in humans so called low risk HPVs such as HPV-6 and HPV-11 cause benign hyperplasia such as
genital warts while high risk HPVs1 for example HPV-16, HPV-18, HPV-31, HPV-33, HPV-52, HPV-54 and HPV-56 can cause cancers such as cervical and penile carcinoma. HPV-5 and HPV-8 cause malignant squamous cell carcinomas of the skin. HPV-2 is found in malignant and non-malignant lesions in cutaneous and squamous epithelium.
In a preferred method of the invention said human papilloma virus is HPV-16 or HPV-18.
Other viruses that have an association with cancer include, Polyomavirus which is associated with colorectal cancer; human herpesvirus-8 is associated with Karposi's sarcoma and Epstein Barr Virus associated with Burkitts lymphoma. RNA viruses are also associated with certain cancers, for example Human T cell leukaemia virus-1 and Hepatitis C virus. A yet further example is HIV and Kaposi's sarcoma
In a preferred method of the invention said hyper-proliferative disease is cancer.
As used herein, the term "cancer" refers to cells having the capacity for autonomous growth, i.e., an abnormal state or condition characterized by rapidly proliferating cell growth. The term is meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. The term "cancer" includes malignancies of the various organ systems, such as those affecting, for example, lung, breast, thyroid, lymphoid, gastrointestinal, and genito-urinary tract, as well as adenocarcinomas which include malignancies such as most colon cancers e.g. colorectal cancer, renal-cell carcinoma, prostate cancer and/or testicular tumours, non- small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus. The term "carcinoma" is art recognized and refers to malignancies of epithelial or endocrine tissues including respiratory system carcinomas, gastrointestinal system carcinomas, genitourinary system carcinomas, testicular carcinomas, breast carcinomas, prostatic carcinomas, endocrine system carcinomas, and melanomas. Exemplary carcinomas include those forming from tissue of the cervix, lung, prostate, breast, head and neck, colon and ovary. The term "carcinoma" also includes carcinosarcomas, e.g., which include malignant tumours composed of carcinomatous and sarcomatous tissues. An "adenocarcinoma" refers to a carcinoma derived from glandular tissue or in which the tumour cells form recognizable glandular structures. The
term "sarcoma" is art recognized and refers to malignant tumors of mesenchymal derivation.
According to a further aspect of the invention there is provided a method to diagnose and optionally treat a subject suffering from a condition which would benefit from the stimulation of apoptosis with a chemotherapeutic agent comprising the steps of: i) providing an isolated sample comprising a cell to be tested; ii) determining the phosphorylation of at least one amino acid residue in a polypeptide comprising an amino acid sequence as represented in Figure 7; iii) comparing the phosphorylation of said polypeptide in said sample to a control sample; and iv) identifying a chemotherapeutic treatment regime that would benefit said subject.
In a preferred method of the invention said sample is additionally tested to determine the p53 genotype of said cell.
In a preferred method of the invention said method includes the administration of at least one chemotherapeutic agent to said subject.
In a preferred method of the invention said chemotherapeutic agent is 5-fluorouracil; preferably 5-fluorouracil is administered with an effective amount of thymidine.
In a preferred method of the invention said phosphorylated amino acid residue is serine 27 in the amino acid sequence represented in Figure 7.
In a further preferred method of the invention said method includes a comparison of the phosphorylation state of serine 27 with the phosphorylation state of serine 47 in the amino acid sequence represented in Figure 7.
In a preferred method of the invention said cell/tissue sample comprises pre-cancerous or cancerous cells.
In a preferred method of the invention said pre-cancerous or cancerous tissue comprises transformed epithelial cells.
Preferably said pre-cancerous or cancerous tissue is derived from the colon.
Colorectal cancer is a cancer which occurs in the large intestine and rectum. The colon can be divided into effectively four sections; the ascending colon; the transverse colon; the descending colon; and the sigmoid colon. Most colorectal cancers arise in the sigmoid colon and develop from "polyps" which can grow for several years before becoming cancerous. The early detection of these pre-cancerous growths is obviously desirable since removal of the polyps is a very effective means to stem the progress of disease. There are various types of colorectal cancer. Most cancers of this type are adenocarcinomas which are malignant growths which begin in the epithelial cells which line the colon and rectum. Other cancers of the colon and rectum include gastrointestinal stromal tumours and lymphomas. In some examples the patient can be asymptomatic and for this reason it is important that early screening is undertaken to identify those patients in which pre-cancerous polyps are forming. The chemotherapeutic agents typically used to treat colorectal cancer include 5-fluorouracil, leucovorin, irinotecan and capecitabine.
In a preferred method of the invention said method further comprises the administration of a vector that includes a nucleic acid molecule that encodes a p53 polypeptide.
In a preferred method of the invention said nucleic acid molecules are part of an expression vector, preferably an expression vector adapted for eukaryotic gene expression.
The use of viruses or "viral vectors" as therapeutic agents is well known in the art. Additionally, a number of viruses are commonly used as vectors for the delivery of exogenous genes. Commonly employed vectors include recombinantly modified enveloped or non-enveloped DNA and RNA viruses, preferably selected from baculoviridiae, parvoviridiae, picornoviridiae, herpesveridiae, poxviridae, adenoviridiae, or picomnaviridiae. Chimeric vectors may also be employed which exploit advantageous elements of each of the parent vector properties (See e.g., Feng, et al.(1997) Nature Biotechnology 15:866-870). Such viral vectors may be wild-type or may be modified by recombinant DNA techniques to be replication deficient, conditionally replicating or replication competent.
Preferred vectors are derived from the adenoviral, adeno-associated viral and retroviral genomes. In the most preferred practice of the invention, the vectors are derived from the human adenovirus genome. Particularly preferred vectors are derived from the human adenovirus serotypes 2 or 5. The replicative capacity of such vectors may be attenuated (to the point of being considered "replication deficient") by modifications or deletions in the E1a and/or E1b coding regions. Other modifications to the viral genome to achieve particular expression characteristics or permit repeat administration or lower immune response are preferred. In the most preferred practice of the invention as exemplified herein, the vector is replication deficient vector adenoviral vector encoding the p53 tumour suppressor gene A/C/N/53 as described in Gregory, et al., United States Patent No. 5,932,210 issued August 3, 1999 (the entire teaching of which is herein incorporated by reference).
Alternatively, the viral vectors may be conditionally replicating or replication competent. Conditionally replicating viral vectors are used to achieve selective expression in particular cell types while avoiding untoward broad spectrum infection. Examples of conditionally replicating vectors are described in Pennisi, E. (1996) Science 274:342- 343; Russell, and S.J. (1994) Eur. J. of Cancer 30A(8):1165-1171. Additional examples of selectively replicating vectors include those vectors wherein a gene essential for replication of the virus is under control of a promoter which is active only in a particular cell type or cell state such that in the absence of expression of such gene, the virus will not replicate. Examples of such vectors are described in Henderson, et al., US 5,698,443; Henderson, et al., US 5,871,726 the entire teachings of which are herein incorporated by reference.
Additionally, the viral genome may be modified to include inducible promoters which achieve replication or expression only under certain conditions. Examples of inducible promoters are known in the scientific literature (see, Yoshida and Hamada (1997) Biochem. Biophys. Res. Comm. 230:426-430; lida, et al. (1996) J. Virol. 70(9):6054- 6059; Hwang, et al.(1997) J. Virol 71(9):7128-7131; Lee, et al. (1997) MoI. Cell. Biol. 17(9):5097-5105; and Dreher, et al.(1997) J. Biol. Chem 272(46); 29364-29371.
The viruses may also be designed to be selectively replicating viruses. Particularly preferred selectively replicating viruses are described in Ramachandra, et al. PCT International Publication No. WO00/22137 International Application No.
PCT/US99/21452 published April 20, 2000 and Howe, J., PCT International Publication No. WO WO0022136, International Application No. PCT/US99/21451 published April 20, 2000.
It has been demonstrated that viruses which are attenuated for replication are also useful in gene therapy. For example the adenovirus dl1520 containing a specific deletion in the E1b55K gene (Barker and Berk (1987) Virology 156: 107) has been used with therapeutic effect in human beings. Such vectors are also described in McCormick US 5,677,178 and US 5,846,945.
It may be valuable in some instances to utilize or design vectors to achieve introduction of the exogenous transgene in a particular cell type. Certain vectors exhibit a natural tropism for certain tissue types. For example, vectors derived from the genus herpesviridiae have been shown to have preferential infection of neuronal cells. Examples of recombinantly modified herpesviridiae vectors are disclosed in US 5,328,688. Cell type specificity or cell type targeting may also be achieved in vectors derived from viruses having characteristically broad infection by the modification of the viral envelope proteins. For example, cell targeting has been achieved with adenovirus vectors by selective modification of the viral genome knob and fibre coding sequences to achieve expression of modified knob and fibre domains having specific interaction with unique cell surface receptors. Examples of such modifications are described in Wickham, et al.(1997) J. Virol 71(11):8221-8229 (incorporation of RGD peptides into adenoviral fibre proteins); Arnberg, et al.(1997) Virology 227:239-244 (modification of adenoviral fibre genes to achieve tropism to the eye and genital tract); Harris and Lemoine (1996) TIG 12(10):400-405; Stevenson, et al.(1997) J. Virol. 71(6):4782-4790; Michael, et al (1995) Gene Therapy 2:660-668 (incorporation of gastrin releasing peptide fragment into adenovirus fibre protein); and Ohno, et al.(1997) Nature Biotechnology 15:763-767 (incorporation of Protein A-IgG binding domain into Sindbis virus).
Other methods of cell specific targeting have been achieved by the conjugation of antibodies or antibody fragments to the envelope proteins (see, e.g. Michael, et al. (1993) J. Biol. Chem 268:6866-6869, Watkins, et al. (1997) Gene Therapy 4:1004-1012; Douglas, et al (1996) Nature Biotechnology 14: 1574-1578. Alternatively, particularly moieties may be conjugated to the viral surface to achieve targeting (see, e.g. Nilson, et al. (1996) Gene Therapy 3:280-286 (conjugation of EGF to retroviral proteins).
In a preferred method of the invention said nucleic acid molecule encoding p53 is represented by the nucleic acid sequence presented in Figure 8.
In a preferred method of the invention said nucleic acid molecule encodes a p53 polypeptide as represented by the amino acid sequence in Figure 9.
In a further preferred method of the invention said subject is further administered an agent that inhibits the activity of the RNA-binding protein HuR.
In a preferred method of the invention said agent is an antibody or fragment thereof.
In an alternative preferred method of the invention said agent is an siRNA; preferably said siRNA is derived from the nucleic acid sequence in Figure 10.
In a preferred method of the invention said nucleic acid molecule that encodes p53 is modified wherein said modification prevents or inhibits the binding of the RNA-binding protein HuR to the 5' and/or 3' leader sequences of p53 mRNA.
In an alternative preferred method of the invention said subject is administered an agent that inhibits the binding of the RNA-binding protein HuR to mRNA that encodes SIRT1.
According to a yet further aspect of the invention there is provided a method to screen for agents that modulate the activity of at least one sirtuin associated with the initiation and/or progression of cancer comprising the steps of: i) forming a preparation comprising at least one sirtuin polypeptide wherein said polypeptide is represented by the amino acid sequence in Figure 7, or a variant thereof, and at least one candidate agent to be tested; and ii) determining the activity of said agent with respect to activity of said polypeptide.
In a preferred method of the invention said agent inhibits the phosphorylation of said polypeptide.
In a further preferred method of the invention said polypeptide is represented by the amino acid sequence in Figure 7.
In a preferred method of the invention said polypeptide is expressed by a cell wherein said cell is transformed or transfected with a nucleic acid molecule that encodes a sirtiun polypeptide. Preferably said nucleic acid molecule is part of a vector adapted for recombinant expression of said nucleic acid molecule. Preferably said vector is provided with a promoter which enables the expression of said nucleic acid molecule to be regulated.
In a preferred method of the invention said cell is derived from the colon, preferably said cell is an epithelial cell which lines the colon.
Throughout the description and claims of this specification, the words "comprise" and "contain" and variations of the words, for example "comprising" and "comprises", means "including but not limited to", and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.
Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.
An embodiment of the invention will now be described by example only and with reference to the following figures:
Figure 1 illustrates cancer cells express elevated levels of SIRT1 protein and this correlates with SIRT1 S27 phosphorylation, a. Schematic of human sirtuins SIRT1-7 showing conserved catalytic domain (black bar) and unique N- and C-terminal domains. b. SIRT1 N-terminal residues 16-55 with sites of phosphorylated serines 27 and 47 indicated, c. lmmunoblot showing SIRT1 protein levels, S27P and S47P between 15 human non-cancer (NC) and cancer (C) cell lines, d. lmmunoblot showing relative levels of SIRT1 , S27P and S47P between non-cancer ARPE-19 cells and isogenic colorectal carcinoma HCT116 p53+/+ and HCT116 p53-/- cells, e, f. Relative levels of total SIRT1 ,
SIRT1 S27P and SIRT1 S47P (Methods), as shown in (d) for ARPE-19 (black bars), HCT116 p53+/+ (grey bars) and HCT116 p53-/- (open bars), g. Relative levels of SIRT1 mRNA between ARPE-19 (black bars), HCT116 p53+/+ (grey bars) and HCT116 p53-/- (open bars);
Figure 2 illustrates 5-FU induces rapid loss of SIRT1 mRNA associated with p53- dependent decrease in total SIRT1 protein in ARPE-19 and HCTΪ 16 cells, a. Levels of SIRT1, laminA/C and GAPDH mRNAs determined by qRT-PCR at 24h 5-FU exposure. b. SIRT1 mRNA levels at Oh, 2h, 6h, 12h and 24h after treatment with 5-FU. c. Protein levels of total SIRT1 , SIRT1 S27P, SIRT1 S47P, p53 and p53 K382Ac at Oh, 2h, 6h, 12h and 24h after treatment with 5-FU. d. Phase contrast images of ARPE-19, HCT116 p53+/+ and HCT116 p53-/- cells after 24h 5-FU. e. Relative numbers of apoptotic cells identified by annexin-V staining after 24h 5-FU;
Figure 3 illustrates that in cancer cells the maintenance of SIRT1 protein and phosphorylation levels is dependent upon JNK2 and p53. a. SIRT1, JNK1 and JNK2 protein levels and b. mRNA levels in ARPE-19 cells at 24h, 48h, 72h and 96h post- transfection with SIRT1 siRNA, JNK2 siRNA or JNK1 siRNA as indicated, c-e. lmmunoblots showing SIRT1 , p53, JNK1 and JNK2 proteins in (c) non-cancer ARPE-19 cells, (d) HCT116 p53+/+ cells and (e) HCT116 p53-/- cells after JNK1 and JNK2 silencing and treatment with 5-FU+U (see text), f. SIRT1 mRNA levels in HCTΪ16 p53+/+ cells after 24h treatment with 5-FU or 5-FU+U;
Figure 4 illustrates a schematic summarising SIRT1 phosphorylation in non-cancer and cancer cells, and the effects of 5FU and/or JNK2 silencing;
Figure 5a is the nucleic acid sequence of human JNK2 variant 1; Figure 5b is the nucleic acid sequence of human JNK2 variant 2; Figure 5c is the nucleic acid sequence of human JNK2 variant 4;
Figure 6a is the amino acid sequence of human JNK2 variant 1 ; Figure 6b is the amino acid sequence of human JNK2 variant 2; Figure 6c is the amino acid sequence of human JNK2 variant 4;
Figure 7a is the nucleic acid sequence of human SIRT1 ; Figure 7b is the amino acid sequence of human SIRT1;
Figure 8 is the nucleic acid sequence of human p53;
Figure 9 is the amino acid sequence of human p53;
Figure 10a is the nucleic acid sequence of the RNA-binding protein HuR; Figure 10b is the amino acid sequence of RNA-binding protein HuR;
Figure 11 is a western blot showing expression in human keratinocytes tranfected with expression vectors for HPV16 E6 and HPV16 E7 oncogenes and that E7 induces differential phosphorylation of SIRTi;
Figure 12 Phenotype of enforced expression of HPV-16 viral transcripts in NHEK cells. a. Digital phase contrast images of NHEK cells at 48 hours post-transfection with E6 or E7 viral transcript expression vectors, b. Colony forming assay of NHEK transfected with E6 or E7 expression vectors; and
Figure 13 JNK-dependent phosphorylation at S27 stabilises exogenous SIRT1 protein. a. Schematic of experimental protocol for RNAi followed by transfection with exogenous SIRT1 expression vector (see text), b. Exogenous expression of SIRT1 in intact HCT116 ceils (lane 2), JNK2-depleted cells (lane 3) and JNK1-depleted cells (lane 4) detected by immunoblotting. Lane 1 = intact, non-transfected cells. Note that in both intact cells and JNK1 -depleted cells the exogenous SIRT1 is phosphorylated on S27 and S47, whereas in JNK2-depleted cells S27P levels reflect endogenous SIRT1 (lanes 1 and 3, asterix), c, d. Time course analyses of SIRT1 protein levels and SIRT1 S27P following addition of cycloheximide in intact (panel c) and JNK2-depIeted (panel d) HCT116 cells as indicated, e. SIRT1 protein levels at indicated times post treatment with cycloheximide (CHX) in intact cells (solid circles, solid line) and in JNK-depleted cells (open circles, dashed line).
Materials and Methods
Cell lines, transfection and drug treatments
Epithelial cancer cell lines RKO, LoVo, DLD-1, HT29, U2OS, SAOS-2, MCF7, HTB-126, HT-1080 and SiHa were obtained from ATCC. Isogenic colorectal carcinoma cell lines HCT116 p53+/+ and HCT116 p53-/- were a kind gift of Bert Vogelstein. Non-cancer cells
were normal diploid fibroblasts (NDF) and ARPE-19 immortalised retinal epithelial cells (ATCC), and normal human embryonic keratinocytes (NHEK, Invitrogen). Cells were cultured according to the supplier's protocols. siRNA sequences, transfection protocols and target validations were as described (Ref. 27 and Methods). For drug treatments, cells were treated 48 hours post-plating with final concentration of 5-FU (375 GM) and uridine (425 DM) as indicated and harvested 24h later. For combined transfection/drug treatment, drugs were applied 24h post-transfection and cells harvested 24h later. For time course analyses cells were harvested at indicated time points post-treatment.
Quantification of mRNA
Cellular mRNAs were extracted for quantitative RT-PCR as previously described27. Primers and thermal cycling conditions were as described27 (Methods); quantifications were performed in triplicate.
lmmunoblotting
Cells were prepared as described (Methods). For immunoblotting equivalent numbers of cells, or equivalent amounts of protein, were loaded in each lane. Antibodies were: Anti- SIRT1 (H-300, Santa Cruz), anti-phosphoserine27-SIRT1 (#2327, Cell Signaling), anti- phosphoserine47-SIRT1 (#2314, Cell Signaling), anti-actin (MAB1501, Chemicon), anti- p53 (DO-1, Santa Cruz), anti-acetylated-p53-lysine382 (#2525, Cell Signaling), anti- JNK1 (F-3, Santa Cruz), anti-JNK2 (#4672, Cell Signaling). Visualisation of bound antibodies was by ECL, with quantitation by densitometry of signals within the linear range.
Microscopy and determination of apoptosis
Phase contrast digital images were captured using an Axiovert 200M microscope (Zeiss). Apoptotic cells were identified by flow cytometry using annexin-V-Fluos (Roche) following the manufacturer's protocol.
Cell Culture
Cells were cultured at 370C in 5% CO∑. Colorectal carcinoma cell lines HCT116 (p53+/+ and isogenic p53-/-), LoVo (p53 wild-type) and HT29 (p53 mutant) were cultured in DMEM (Gibco); colorectal carcinoma cell line DLD-1 (p53 mutant) was cultured in RPMI
1640 (Gibco) supplemented with 1mM sodium pyruvate; colorectal carcinoma cell line
RKO (p53 wild-type) was cultured in MEM (Gibco); osteogenic sarcoma cell lines U20S (p53 wild-type) and SAOS-2 (p53 null) were cultured in McCoy's 5A modified (ATCC); fibrosarcoma cell line HT-1080 (p53 wild-type) was cultured in EMEM (ATCC); breast carcinoma cell line MCF7 (p53 wild-type) was cultured in EMEM (ATCC) supplemented with 10 μg ml'1 insulin; breast carcinoma cell line HTB-126 (p53 mutant) was cultured in DMEM (ATCC) supplemented with 10 μg ml"1 insulin; human papilloma virus type 16- transformed cervical carcinoma cell line SiHa (p53 wild-type) was cultured in EMEM (ATCC) supplemented with 1 mM sodium pyruvate and 0.1 mM nonessential amino acids; spontaneously immortalised non-cancer retinal epithelial cell line ARPE-19 was cultured in DMEM:F12 (Gibco); normal diploid lung fibroblast (NDF) WI-38 was cultured in MEM (Gibco) supplemented withi mM sodium pyruvate and 0.1 mM nonessential amino acids. All media were supplemented with 10% foetal bovine serum, and either 2 mM L-glutamine (LoVo, HT29, DLD-1, RKO, HT-1080, MCF7, SiHa, WI-38) or 4 mM L- glutamine (HCT116, U2OS, SAOS-2, HTB-126, ARPE-19). Normal human epidermal keratinocytes (NHEK, Invitrogen) were cultured in defined serum-free media (KSF) in collagen-IV (Sigma) coated flasks. For experiments, cell lines were used between passage 2-4 following removal from liquid nitrogen.
Transfection and Drug Treatments
Cells for transfection and/or drug treatment were plated at a density of 6x 104 (ARPE-19) or 1.4x 105 (HCT116) per well in 6-well plates. For the experiment in Fig3a, ARPE-19 cells were plated at a density of 4x104 per well. Transfections were performed 24 hours post-plating in Opti-MEM (Gibco) using Oligofectamine (Invitrogen) according to the manufacturer's instructions. Chemically synthesized, HPLC-purified siRNAs were obtained from Qiagen or Dharmacon. SIRT1 siRNA sequence has been described27. JNK1 siRNA sequences were: Sense 5'-CUCCACCACCAAAGAUCCC(dTdT)-3I 1 antisense 5'-GGGAUCUUUGGUGGUGGAG(dTdT)-3'. JNK2 siRNA sequences were: Sense 5'-GAGCUGGUGAAAGGUUGUG(dTdT)-3', antisense 5'-CACAACCUUU CACCAGCUC(dTdT)-3'. Specificities of SIRT1 siRNA, JNK1 siRNA and JNK2 siRNA have been validated previously27 (Ahmed and Milner, in submission). Cells were harvested for analysis 48h post-transfection, except where indicated otherwise. For drug treatment, drugs were applied by complete media replacement 48h post-plating at final concentration 375 μM (5-FU) or 425 μM (uridine). Cells were harvested for analysis 24h following application of drugs, or at the indicated timepoints for time-course analysis. For combined transfection/drug experiments, drugs were applied approximately 20 hours
post-transfection. Cells from combined transfection/drug experiments were harvested for analysis after 24 hours of drug exposure (~48 hours post-transfection).
Protein Preparation and Immunoblottinq
For preparation of total protein lysates, cell counts or protein assay was performed, with the method chosen consistent within each experiment. Cells were lysed in lysis buffer IPAMN (10 mM TRIS base pH 8.0, 140 mM NaCI, 2 mM CaCI2, 0.5% NP-40, 5 U ml"1 micrococcal nuclease) for 3 minutes at room temperature followed by addition of 0.25x volumes of 6x SDS-PAGE sample buffer and brief heating to 900C. Samples for protein assay were withdrawn before addition of 6x SDS-PAGE sample buffer, and assayed using BCA Protein Assay Kit (Pierce) according to the manufacturer's instructions. Equivalent numbers of cells, or equivalent amounts of protein, were electrophoresed on 10% or 15% SDS-PAGE, electroblotted to Protran membrane (Schleicher&Schuell) using a wet-blot transfer system, blocked for 1 hour at room temperature and probed with primary antibodies overnight at 40C. Antibodies were: Anti-SIRT1 (H-300, Santa Cruz), anti-phosphserine27-SIRT1 (#2327, Cell Signaling), anti-phosphoserine47-SIRT1 (#2314, Cell Signaling), anti-actin (MAB1501 , Chemicon), anti-p53 (DO-1, Santa Cruz), anti-acetylated-p53-lysine382 (#2525, Cell Signaling), anti-JNK1 (F-3, Santa Cruz), anti- JNK2 (#4672, Cell Signaling). Bound antibodies were visualised by ECL (Roche). Densitometry was performed from under-exposed images within the linear range, using Quantity One analysis software (BioRad).
Quantitative RT-PCR
Relative mRNA levels were quantitated by realtime RT-PCR. Primer sequences and thermal cycles for GAPDH and LaminA/C have been described previously27. SIRT1 primers δ'-CTAATTCCAAGTTCCATACCC-S' and 5'-CTGAAGAATCTGGTGGTGAAG-3I were used in the thermal cycle: 5O0C for 30 minutes, 940C for 15 minutes, followed by 35 cycles of 940C for 30 seconds, 550C for 30 seconds, 720C for 30 seconds, then 750C for 15 seconds before the plate was read. JNK1 primers 5'- CCAGGAAGGGACTATATTGATC-3' and δ'-TCTCTCCTCCAAGTCCATAACT-S' were used in the thermal cycle: 500C for 30 minutes, 940C for 15 minutes, followed by 35 cycles of 940C for 30 seconds, 570C for 30 seconds, 720C for 30 seconds, then 750C for 15 seconds before the plate was read. JNK2 primers 5'-GAAGCCTAGCAACATTGTTG- 3' and 5'-GATCAATATGGTCAGTGCCT-3I were used in the thermal cycle: 5O0C for 30
minutes, 940C for 15 minutes, followed by 35 cycles of 940C for 30 seconds, 550C for 30 seconds, 720C for 30 seconds, then 750C for 15 seconds before the plate was read. All RT-PCR quantifications were performed in triplicate.
Microscopy and Determination of Apoptosis
Digital phase contrast images of cells were taken on an Axiovert 200M microscope. Apoptotic cells were identified using Annexin-V-Fluos kit (Roche) with analysis by CellQuest software on FACsCalibur (BD).
EXAMPLE 1
We have asked if SIRT1 is subject to post-translational regulation. Putative phosphorylation sites at S27 and S47 within the unique SIRT1 N-terminal domain (Fig. 1a and b) have previously been revealed by mass spectrometry23. To investigate the significance of these sites we screened a series of human cell lines using commercially available antisera raised against synthetic SIRT1 S27P and S47P phosphopeptides (Methods). SIRT1 knock-down by RNA interference (RNAi) showed equivalent knockdown of S27P and S47P in HCT116 cells, thus validating anti-SIRT1 activity of the anti- phosphopeptide antisera (Fig. 1c). This result also demonstrates that both SIRT1 S27P and S47P remain detectable even when cellular levels of total SIRT1 are reduced > 30- fold (as determined by gel scanning, Methods).
Under basal conditions of culture SIRT1 S27P appeared restricted to cancer cells, being undetectable in non-cancer ARPE-19 epithelial cells, primary human keratinocytes
(NHEK) and normal diploid fibroblasts (NDFs) (Fig. 1c). In contrast SIRT1 S47P was evident in both non-cancer and cancer cell lines (with the exception of primary human epidermal keratinocytes in which S47P was undetectable; Fig. 1c). S47P levels tended to parallel total SIRT1 protein (SIRT1:S47P ratio range 0.8 to 1.5, as determined by gel scanning, see Methods) suggesting constitutive phosphorylation at this site. In contrast
S27P detection was variable relative to total SIRT1 in the different cell lines (Fig. 1c;
SIRT1:S27P ratio range 3.4 to 34). The observed variability in S27 phosphorylation relative to total SIRT1 protein indicates that S27 phosphorylation is subject to cellular regulation.
Total SIRT1 protein levels were generally high in cancer relative to non-cancer cells (Fig.1c; see also below). The one exception was HT29 colorectal cancer cells which expressed low levels of total SIRT1. The HT29 cells also differed from the remaining cancer cell lines in that SIRT1 was un-phosphorylated on S27 (Fig. 1c). Thus S27P is variable relative to total SIRT1 and correlates with the elevated SIRT1 protein levels observed in cancer cells under basal conditions of growth.
More detailed comparison of SIRT 1 protein levels in non-cancer versus cancer cell lines employed ARPE-19 cells (spontaneously immortalised human retinal epithelial cells of non-cancerous origin) and HCT116 p53+/+ and p53-/- isogenic human colorectal cancer epithelial cells24. Comparison of SIRT1 protein levels on a per cell basis revealed -15 to 20-fold higher SIRT1 levels in HCT116 cells compared with ARPE-19 cells (Fig. 1d, 1e & 1f). S47P paralleled SIRT1 levels, whilst the S27P:SIRT1 ratio was approximately fourfold higher in HCT116 p53-/- cells compared with HCT116 p53+/+ cells (Fig. 1e & 1f). This suggests that the presence of p53 may influence phosphorylation of SIRT1 at S27 (see also below). Importantly SIRT1 mRNA levels were similar in both ARPE-19, HCT116 p53+/+ and HCT116 p53-/- cells (Fig. 1g). Thus the observed differences in SIRT1 protein levels between ARPE-19 and HCT116 cells were not attributable to differences in gene expression levels or mRNA stability. They may therefore reflect differences in the efficiency of mRNA translation and/or SIRT1 protein stability. However, since SIRT1 is not thought to be regulated via variable translation efficiency, our results indicate that high SIRT1 protein levels in human cancer cells reflect abnormally increased protein stability. Since SIRT1 protein stability shows a positive correlation with phosphorylation at S27 it is possible that S27P prolongs the half-life of cellular SIRT1 protein.
EXAMPLE 2
We next asked if 5-FU induces any changes in SIRT1 levels and/or phosphorylation status. 5-FU is a clinically important anti-cancer drug and is the treatment of choice for colorectal cancer. The mechanism of action of 5-FU is complex and includes perturbation of DNA synthesis culminating in DNA damage, and also incorporation into newly synthesised RNAs with consequential inhibition of RNA processing25'26. In the present study treatment of cells with 5-FU for 24h resulted in 80% depletion of SIRT1 mRNA, whilst lamin A/C and GAPDH mRNA levels were relatively unaffected (Fig. 2a).
More detailed time-course analysis revealed a rapid loss of SIRT1 mRNA following
administration of 5-FU, with estimated U,2< 2h in HCT116 cells and tV2~ 4h in ARPE-19 cells (Fig. 2b). The normal half-life of SIRT1 mRNA (~ 8 h) is known to be dependent upon HuR-SIRTI mRNA complexing14'15. In the absence of HuR the half life of SIRT1 mRNA falls to around 1.5h. Moreover, oxidative stress triggers dissociation of [HuR- SIRT1 mRNA] complexes and thus promotes SIRT1 mRNA decay. Our own independent results now indicate that the anti-cancer drug 5-FU also promotes SIRT1 mRNA decay (see above and Fig. 2b). Future studies will explore the potential involvement of HuR in this effect. For the purposes of the present study the loss of SIRT1 mRNA is an important backdrop for interpreting the effects of 5-FU upon SIRT1 phosphorylation and SIRT1 protein stability.
In ARPE-19 cells the levels of SIRT1 protein increased 6h after 5-FU treatment and subsequently declined by 24h (Fig. 2c, left hand panel). Cellular SIRT1 protein levels in 5-FU-treated HCT116 p53+/+ cells were stable over 12h, but declined by 24h post- treatment (Fig. 2c, centre panel). Reduced SIRT1 protein levels correlated with loss of S27 phosphorylation (Fig. 2c, centre panel). Importantly, comparison with isogenic HCT116 p53-/- cells revealed that, in the absence of p53, the level of SIRT1 protein remains constant up to at least 48h post treatment with 5-FU (Fig.2c, right hand panel, 48hr data not shown). In addition, phosphorylation at S27 (lost in HCT116 p53+/+ cells) was retained in HCT116 p53-/-cells exposed to 5-FU (Fig. 2c, right hand panel). These observations identify SIRT1 as a regulable target of the anti-cancer drug 5-FU and also implicate p53 as an essential player linking 5-FU-induced effects with SIRT1 S27 phophorylation/protein stability. Thus p53 is involved in the regulation of SIRT1 protein turnover in the presence of 5FU.
In both ARPE-19 and HCT116 ceils the drug 5-FU induces a p53 response with p53 protein stabilisation and up-regulation of p53 target genes p21 and HDM2 (Fig. 2c and data not shown). SIRT1 is known to deacetylate activated p53 in mouse embryonic fibroblasts and thus down-regulate the p53 response11. This is entirely consistent with our present results using human epithelial cells (ARPE-19) in which the p53 response was attenuated and acetylation of p53 was undetectable (Fig. 2c, left hand panel). The cells remained viable (Fig. 2d, 2e). In contrast HCT116 p53+/+ colorectal cancer cells displayed a sustained p53 response to 5-FU and this correlated with induction of p53 K382 acetylation and apoptosis (Fig. 2c centre panel and 2d, 2e). Similar differences between normal and cancerous cells may contribute to the preferential anti-cancer effects of 5-FU in the clinic.
EXAMPLE 3
Previously we have observed that selective silencing of JNK2 by RNA interference (RNAi) results in reduced levels of SIRT1 protein (Ahmed and Milner, unpublished observations and Fig. 3a centre panel). This unexpected effect was attributed to decreased SIRT1 protein stability since SIRT1 mRNA levels remained constant (Fig. 3a and b, centre panels). The effect was specific to JNK2 since JNK1 silencing had no effect upon SIRT1 protein levels (Fig 3a and b, right hand panels). Also there was no reciprocal effect of SIRT1 silencing on JNK2 protein levels (Fig. 3a, left hand panel). In the light of our present observations we considered that the JNK2 kinase may, directly or indirectly, influence SIRT1 protein stability and that such an effect may operate via SIRT1 phosphorylation.
Depletion of JNK1 by RNAi had no effect upon SIRT1 protein levels nor upon S27 or S47 phosphorylation in ARPE-19, HCT116 p53 +/+ or HCT116 p53-/- cells (Fig. 3c- e). In contrast depletion of JNK2 in HCT116 p53 +/+ cells resulted in loss of SIRT1 S27P, reduced SIRT1 protein levels and barely detectable S47P (Fig. 3d). These effects on SIRT1 protein were evident in the absence of any reduction in SIRT1 mRNA levels (not shown, results similar to those observed for ARPE19 cells Fig 3b, middle panel). In parallel cultures cells were treated with 5-FU in the presence of excess uridine (5-FU + U) which rescues SIRT1 mRNA levels (Fig. 3f). Thus we were able to compare the effects of 5-FU and of JNK2 silencing whilst maintaining SIRT1 mRNA levels. In HCT116 p53+/+ cells 5-FU+U alone caused loss of S27P accompanied by partial depletion of total SIRT1 protein paralleled by S47P decrease (Fig. 3d). Strikingly, 5-FU+U treatment of JNK2-depleted cells resulted in total loss of SIRT1 protein (Fig. 3d). The ceils died by apoptosis.
In HCT116 p53-/- cells JNK2 silencing or treatment with 5-FU+U had little effect on SIRT1 protein levels or phosphorylation status (Fig. 3e). This indicates that the above observations with HCT1116 p53+/+ cells (Fig. 3d) are p53-dependent. Combined 5-FU plus JNK2 silencing induced only partial reduction of SIRT1 and total protein, S27P and S47P remained detectable (Fig. 3e). Similarly in ARPE-19 cells total SIRT1 levels and S47P were also only partially responsive to JNK2 depletion and 5-FU+U (Fig. 3c). The cells also remained viable. Thus although ARPE-19 cells are positive for p53 their SIRT1 status proved relatively resistant to JNK2 depletion and 5-FU+U treatment.
Given their diverse roles in health and disease the sirtuins are recognised as important targets for therapeutic manipulation. Our discovery of post-translational regulation via the variable N-terminal sirtuin domain identifies a route for selective therapeutic targeting of SIRT1 without compromising normal functioning of other sirtuins. Moreover the observed link between S27 phosphorylation and abnormal SIRT1 protein accumulation in cancer cells identifies SIRT1 phosphorylation as a promising target for the development of novel anti-cancer therapies.
EXAMPLE 4
Figure 11 illustrates expression levels and phosphorylation status of SIRT1 protein in primary human keratinocytes following expression of vectors encoding HPV16 E6 and
HPV16 E7 oncoproteins. Cells were transfected with expression vectors and analysed
48h post-transfection. lmmunoblots showing detection of HPV E6, HPV E7, total SIRT1,
SIRT1 S27P and SIRT1 S47P as indicated down right hand side of panels. Actin loading control is also shown. Lanes: vector = vector only control transfection; E6 = HPV16 E6 expression vector; E7 = HPV16 E7 transfection vector.
EXAMPLE 5
To further explore the relationship between SIRT1 and JNK2 we expressed exogenous SIRT1 in HCT116 p53+/+ cells in which JNK2 had been depleted by RNAi (Methods and Fig. 13a). When expressed in intact cells exogenous SIRT1 protein was phosphorylated at both S27 and S47 (Fig. 13b, lane 2). However, when expressed in JNK2-depleted cells the exogenous SIRT1 protein appeared non-phosphorylated at S27: only endogenous SIRT1 S27P was detectable (Fig. 13b, lanes 1 and 3, asterix). In addition total exogenous SIRT1 protein levels were reduced in JNK2-depleted cells (Fig. 13b, lane 3 cp. lane 2, SIRT1), consistent with reduced SIRT1 protein stability in the absence of S27 phosphorylation. In JNK2-depleted cells exogenous SIRT1 S47P was clearly detectable (Fig. 13b lanes 1 and 3, dagger), albeit at reduced levels relative to those in intact cells (Fig. 13b, lanes 2 and 3) indicating that S27P can influence SIRT1 S47 kinase/phosphatase activity. When JNK1 was silenced by RNAi instead of JNK2 the exogenous expression of SIRT1 and its phosphorylation were indistinguishable from the intact controls (Fig. 13b, cp. lanes 2 and 4). Thus JNK2, but not JNK1, is required for S27 phosphorylation and associated accumulation of SIRT1 protein.
The above results indicate that depletion of JNK2 results in the inability of HCT116 cells to phosphorylate newly expressed SIRT1 protein at S27. Reduced accumulation of SIRT1 protein under these conditions is consistent with the premise that JNK2- dependent phosphorylation of SIRT1 at S27P stabilises the SIRT1 protein. This was confirmed by time course studies in which exogenous SIRT1 protein levels were monitored following inhibition of protein synthesis by cycloheximide. As expected in both intact (Fig. 13c) and in JNK2-depleted cells (Fig. 13d) the p53 protein exhibited a short half-life (<2h) following addition of cycloheximide, whilst actin protein levels were stable over 9h under both conditions (Fig. 13c, d). In intact cells exogenous SIRT1 protein was phosphorylated at S27 (Fig. 13c) and was also stable over 9hr (Fig. 13c and 13e). However, in JNK2-depleted cells exogenous SIRT1 protein lacked S27P (Fig. 13d) and protein levels declined with a half life of approximately 2hrs (Fig. 13d and 13e). We conclude that JNK2 is required, directly or indirectly, for phosphorylation of SIRT1 at S27 and that this is linked with stabilisation of SIRT1 protein in HCT116 cancer cells.
References
1. McBumey, M.W. et al. The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. MoI. Cell Biol. 23, 38-54 (2003).
2. Cheng, H. L. et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1 )-deficient mice. PNAS USA 100, 10794-10799 (2003).
3. Rodgers, JT. et al. Nutrient control of glucose homeostasis through a complex of PGC-1 alpha and SIRT1. Nature 434, 113-118 (2005).
4. Hallows, W.C., Lee, S. & Denn, J. M. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. PNAS USA 103, 10230-10235 (2006). 5. Brunet, A. et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303, 2011-2015 (2004).
6. Chua, K.F. et al. Mammalian SIRT1 limits replicative lifespan in response to chronic genotoxic stress. Cell Metab. 2, 67-76 (2005).
7. Qiu, W. et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J.
Biol. Chem. 281, 21745-21754 (2006).
8. Yuan, Z., Zhang, X., Sengupta, N., Lane, W.S. & Seto, E. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. MoI. Cell 27, 149-162 (2007).
9. Imai, S., Armstrong, CM., Kaeberlein, M. & Guarente, L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403,
793-800 (2000).
10. Blander, G. & Guarente, L. The SIR2 family of protein deacetylases. Annu. Rev. Biochem. 73, 417-435 (2004).
11. Langley, E. et al. Human SIR2 deacetylates p53 and antagonizes PML/p53induced cellular senescence. EMBO J. 21, 2382-96 (2002). 12. Chen, W.Y. et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123, 437-448 (2005).
13. Zhang, Q. et al. Metabolic regulation of SIRT1 transcription via a HIC1:CtBP corepressor complex. PNAS USA 104, 829-833 (2007).
14. Abdelmohsen, K. et al. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. MoI. Cell 25, 543-557 (2007).
15. Wilusz, CJ. & Wilusz, J. HuR-SIRTI: The hairy world of posttranscriptional control. MoI. Cell 25, 485-487 (2007).
16. Vaquero, A. et al. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. MoI. Ce// 16, 93-105 (2004). 17. Senawong, T. et al. Involvement of the histone deacetylase SIRT1 in chicken ovalbumin upstream promoter transcription factor (COUP-TF)-interacting protein 2- mediated transcriptional repression. J. Biol. Chem. 278, 43041-43050 (2003).
18. Senawong, T., Peterson, V.J. & Leid, M. BCL11A-dependent recruitment of SIRT1 to a promoter template in mammalian cells results in histone deacetylation and transcriptional repression. Arch. Biochem. Biophys. 434, 316-325 (2005).
19. Luo, J. et al. Negative control of p53 by Sir2α promotes cell survival under stress. Ce// 107, 137-148 (2001).
20. Vaziri, H. et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Ce// 107, 149-159 (2001). 21. Barak, Y., Juven, T., Haffner, R. & Oren, M. Mdm-2 expression is induced by wild-' type p53 activity. EMBO J 12, 461-468 (1993).
22. Moll, U.M. & Petrenko, O. The MDM2-p53 interaction. MoI. Cancer Res. 1, 1001- 1008 (2003).
23. Beausoleil, S.A. et al. Large-scale characterisation of HeLa cell nuclear phosphoproteins. PNAS USA 101, 12130-12135 (2004).
24. Bunz, et al., Disruption of p53 in human cancer cells alters the responses to chemotherapeutic agents. J. Clin. Invest. 104, 263-269 (1999).
25. Noordhuis, P. et al. 5-Flouorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Annals Oncol. 15, 1025-1032 (2004).
26. Longley, D.B., Harkin, D.P. & Johnston, P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3, 330-38 (2003).
27. Ford, J., Jiang, M. & Milner, J. Cancer-specific functions of SIRT1 enables human epithelial cancer cell growth and survival. Cancer Res. 65, 10457-10463 (2005).
Claims
1. A combined therapeutic composition comprising: an inhibitor of JNK2 and at least one chemotherapeutic agent.
2. A composition according to claim 1 wherein JNK2 is encoded by a nucleic acid molecule comprising a nucleic acid sequence as shown in Figure 5a, 5b or 5c or a nucleic acid molecule that hybridizes under stringent hybridization conditions to the sequence in Figure 5a, 5b or 5c and that encodes a polypeptide which has the activity of JNK2.
3. A composition according to claim 2 wherein JNK2 is encoded by a nucleic acid molecule as represented in Figure 5a, 5b or 5c.
4. A composition according to claim 2 or 3 wherein said nucleic acid molecule encodes a polypeptide as represented by the amino acid sequence as shown in Figure 6a, 6b or 6c.
5. A composition according to any of claims 2-4 wherein said inhibitor of JNK2 is a siRNA molecule derived from the nucleic acid sequence in Figure 5a, 5b or 5c.
6. A composition according to claim 5 wherein said JNK2 siRNA a hybrid nucleic acid molecule comprising a first part that comprises a duplex ribonucleic acid (RNA) molecule and a second part that comprises a single stranded deoxyribonucleic acid (DNA) molecule.
7. A composition according to claim 6 wherein said single stranded DNA molecule is contiguous with the sense strand of said duplex RNA molecule.
8. A composition according to claim 6 wherein said single stranded DNA molecule is contiguous with the antisense strand of said duplex RNA molecule.
9. A composition according to claim 6 wherein said single stranded DNA molecule is extended and is contiguous with both sense and antisense strands of said duplex RNA molecule.
10. A composition according to claim 6 wherein said single stranded DNA molecule comprises a 3' terminal nucleic acid sequence wherein said sequence is adapted over at least part of its length to anneal by complementary base pairing to a part of said single stranded DNA to form a double stranded DNA structure.
11. A composition according to claim 10 wherein said single stranded DNA molecule comprises at least one copy of the sequence d (GCGAAGC).
12. A composition according to any of claims 6-11 wherein the single stranded DNA molecule is at least 7 nucleotides in length.
13. A composition according to any of claims 6-11 wherein said single stranded DNA molecule is between 10-40 nucleotide bases in length.
14. A composition according to any of claims 6-11 wherein said single stranded DNA molecule is 15-30 nucleotides in length.
15. A composition according to any of claims 6-14 wherein said duplex RNA molecule is at least 18 base pairs in length.
16. A composition according to claim 15 wherein said duplex RNA molecule is between 18bp and 29bp in length.
17. A composition according to claim 16 wherein said duplex RNA molecule is 21 bp in length.
18. A composition according to any of claims 1-4 wherein said inhibitor is a peptide or modified peptide.
19. A composition according to any of claims 1-4 wherein said inhibitor is a polypeptide.
20. A composition according to claim 19 wherein said polypeptide is a monoclonal antibody, or fragment thereof, that binds JNK2.
21. A composition according to claim 20 wherein said antibody fragment is a single chain antibody fragment.
22. A composition according to any of claims 1-21 wherein said chemotherapuetic agent is an anti-metabolic drug.
23. A composition according to claim 22 wherein said drug is a purine analogue.
24. A composition according to claim 22 wherein said drug is a pyrimidine analogue.
25. A composition according to claim 22 wherein said chemotherapeutic agent is selected from the group consisting of: 5-fluorouracil, fluoroirinotecan and capecitabine.
26. A composition according to claim 25 wherein said chemotherapeutic agent is 5- fluorouracil.
27. A composition according to claim 25 or 26 wherein said composition includes leucovorin.
28. A method to diagnosis a disease condition that is associated with the phosphorylation of a sirtuin polypeptide comprising: i) providing an isolated sample comprising a cell to be tested; ii) determining the phosphorylation of at least one amino acid residue in a sirtuin polypeptide; and Hi) comparing the phosphorylation of said polypeptide in said sample to a control sample.
29. A method according to claim 28 wherein said sirtuin is SIRT1.
30. A method according to claim 29 wherein said sirtuin is represented by the amino acid sequence in Figure 7.
31. A method according to claim 30 wherein said phosphorylation is at serine 27 as shown in Figure 7.
32. A method according to claim 31 wherein said method includes a comparison of the phosphorylation of serine 27 with the phosphorylation of serine 47 in the amino acid sequence represented in Figure 7.
33. A method according to any of claims 28-32 wherein said disease condition is a hyper-proliferative disease.
34. A method according to claim 33 wherein said disease is a viral infection caused by a pathogenic virus.
35. A method according to claim 34 wherein said disease is viral induced cancer.
36. A method according to claim 35 wherein said disease is a viral induced cancer resulting form a human papilloma virus (HPV) infection.
37. A method according to claim 36 wherein said human papilloma virus is HPV-16 or HPV-18.
38. A method according to claim 37 wherein said hyper-proliferative disease is cancer.
39. A method according to claim 38 wherein said cell sample comprises In a preferred comprises pre-cancerous or cancerous cells.
40. A method according to claim 39 wherein said pre-cancerous or cancerous tissue comprises transformed epithelial cells.
41. A method according to any of claims 38-40 wherein said pre-cancerous or cancerous tissue is derived from the colon.
42. A method to diagnose and optionally treat a subject suffering from a condition which would benefit from a stimulation of apoptosis with a chemotherapeutic agent comprising the steps of: i) providing an isolated sample comprising a cell to be tested; ii) determining the phosphorylation of at least one amino acid residue in a sirtuin polypeptide; iii) comparing the phosphorylation of said polypeptide in said sample to a control sample; and iv) identifying a chemotherapeutic treatment regime that would benefit said subject.
43. A method according to claim 42 wherein said sirtiun is represented by the amino acid sequence in Figure 7.
44. A method according to claim 42 or 43 wherein said sample is additionally tested to determine the p53 genotype of said cell.
45. A method according to any of claims 42-44 wherein said phosphorylated amino acid residue is serine 27 in the amino acid sequence represented in Figure 8.
46. A method according to any of claims 42-45 wherein said method includes a comparison of the phosphorylation state of serine 27 with the phosphorylation state of serine 47 in the amino acid sequence represented in Figure 8.
47. A method according to any of claims 42-46 wherein said method includes the administration of at least one chemotherapeutic agent to said subject.
48. A method according to any of claims 42-47 wherein said chemotherapeutic agent is 5-fluorouracil.
49. A method according to claim 48 wherein 5-fluorouracil is administered with an effective amount of thymidine.
50. A method according to any of claims 42-49 wherein said ceil sample comprises pre-cancerous or cancerous cells.
51. A method according to claim 50 wherein said pre-cancerous or cancerous cell comprises transformed epithelial cells.
52. A method according to claim 50 or 51 wherein said pre-cancerous or cancerous cell is derived from the colon.
53. A method according to any of claims 42-52 wherein said method further comprises the administration of a vector that includes a nucleic acid molecule that encodes a p53 polypeptide.
54. A method according to claim 53 wherein said nucleic acid molecule encoding p53 is represented by the nucleic acid sequence presented in Figure 8.
55. A method according to claim 53 wherein said nucleic acid molecule encodes a p53 polypeptide as represented by the amino acid sequence in Figure 9.
56. A method according to any of claims 42-55 wherein said subject is further administered an agent that inhibits the activity of the RNA-binding protein HuR.
57. A method according to claim 56 wherein said agent is an antibody or fragment thereof.
58. A method according to claim 56 wherein said agent is a siRNA.
59. A method according to claim 58 wherein said siRNA is derived from the nucleic acid sequence in Figure 10.
60. A method according to claim 56, 58 or 59 wherein said nucleic acid molecule that encodes p53 is modified wherein said modification prevents or inhibits the binding of the RNA-binding protein HuR to the 5' and/or 31 leader sequences of p53 mRNA.
61. A method according to claim 56 wherein said subject is administered an agent that inhibits the binding of the RNA-binding protein HuR to mRNA that encodes SIRT1.
62. A method to screen for agents that modulate the activity of at least one sirtuin associated with the initiation and/or progression of cancer comprising the steps of: i) forming a preparation comprising at least one sirtuin polypeptide wherein said polypeptide is represented by the amino acid sequence in Figure 7, or a variant thereof, and at least one candidate agent to be tested; and ii) determining the activity of said agent with respect to activity of said polypeptide.
63. A method according to claim 62 wherein said agent inhibits the phosphorylation of said polypeptide.
64. A method according to claim 62 or 63 wherein said polypeptide is represented by the amino acid sequence in Figure 7.
65. A method according to any of claims 62-64 wherein said polypeptide is expressed by a cell wherein said cell is transformed or transfected with a nucleic acid molecule that encodes a sirtiun polypeptide.
66. A method according to claim 65 wherein said nucleic acid molecule is part of a vector adapted for recombinant expression of said nucleic acid molecule.
67. A method according to claim 65 or 66 wherein said cell is derived from the colon.
68. A method according to claim 67 wherein said cell is an epithelial cell which lines the colon.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08788343A EP2182985A2 (en) | 2007-08-17 | 2008-08-15 | Combination therapy |
US12/673,813 US20110060028A1 (en) | 2007-08-17 | 2008-08-15 | Combination therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0716072.4A GB0716072D0 (en) | 2007-08-17 | 2007-08-17 | Therapy |
GB0716072.4 | 2007-08-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009024763A2 true WO2009024763A2 (en) | 2009-02-26 |
WO2009024763A3 WO2009024763A3 (en) | 2010-04-29 |
Family
ID=38566556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2008/002775 WO2009024763A2 (en) | 2007-08-17 | 2008-08-15 | Combination therapy |
Country Status (4)
Country | Link |
---|---|
US (1) | US20110060028A1 (en) |
EP (1) | EP2182985A2 (en) |
GB (1) | GB0716072D0 (en) |
WO (1) | WO2009024763A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011036450A3 (en) * | 2009-09-28 | 2011-07-28 | The University Of York | Splice variants |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999009214A1 (en) * | 1997-08-13 | 1999-02-25 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions and methods for the modulation of jnk proteins |
WO2001034792A2 (en) * | 1999-11-12 | 2001-05-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the diminution or elimination of various cancers |
WO2005074921A1 (en) * | 2004-02-09 | 2005-08-18 | University Of Zurich | Treatment of atherosclerosis |
WO2006125977A2 (en) * | 2005-05-25 | 2006-11-30 | The University Of York | Hybrid interfering rna |
-
2007
- 2007-08-17 GB GBGB0716072.4A patent/GB0716072D0/en not_active Ceased
-
2008
- 2008-08-15 EP EP08788343A patent/EP2182985A2/en not_active Withdrawn
- 2008-08-15 US US12/673,813 patent/US20110060028A1/en not_active Abandoned
- 2008-08-15 WO PCT/GB2008/002775 patent/WO2009024763A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999009214A1 (en) * | 1997-08-13 | 1999-02-25 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions and methods for the modulation of jnk proteins |
WO2001034792A2 (en) * | 1999-11-12 | 2001-05-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the diminution or elimination of various cancers |
WO2005074921A1 (en) * | 2004-02-09 | 2005-08-18 | University Of Zurich | Treatment of atherosclerosis |
WO2006125977A2 (en) * | 2005-05-25 | 2006-11-30 | The University Of York | Hybrid interfering rna |
Non-Patent Citations (4)
Title |
---|
BOST FREDERIC ET AL: "The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 272, no. 52, 26 December 1997 (1997-12-26), pages 33422-33429, XP002169470 ISSN: 0021-9258 * |
FUCHS SERGE Y ET AL: "JNK targets p53 ubiquitination and degradation in nonstressed cells" GENES AND DEVELOPMENT, COLD SPRING HARBOR LABORATORY PRESS, PLAINVIEW, NY, US, vol. 12, no. 17, 1 January 1998 (1998-01-01), pages 2658-2663, XP002169469 ISSN: 0890-9369 * |
JIANG MING ET AL: "A bi-functional siRNA construct induces RNA interference and also primes PCR amplification for its own quantification" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 33, no. 18, 7 October 2005 (2005-10-07), pages e151-1, XP002408837 ISSN: 0305-1048 * |
ZHANG HONG ET AL: "Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT116 cells." THE JOURNAL OF BIOLOGICAL CHEMISTRY 15 NOV 2002, vol. 277, no. 46, 15 November 2002 (2002-11-15), pages 43648-43658, XP002559045 ISSN: 0021-9258 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011036450A3 (en) * | 2009-09-28 | 2011-07-28 | The University Of York | Splice variants |
Also Published As
Publication number | Publication date |
---|---|
EP2182985A2 (en) | 2010-05-12 |
US20110060028A1 (en) | 2011-03-10 |
WO2009024763A3 (en) | 2010-04-29 |
GB0716072D0 (en) | 2007-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fan et al. | Derepression of c‐Fos caused by microRNA‐139 down‐regulation contributes to the metastasis of human hepatocellular carcinoma | |
Huang et al. | miR-5100 promotes tumor growth in lung cancer by targeting Rab6 | |
Huang et al. | Attacking c-Myc: targeted and combined therapies for cancer | |
JP5976643B2 (en) | Methods and compositions for specific inhibition of beta-catenin by double stranded RNA | |
JP2013534424A (en) | Methods and compounds for the specific inhibition of androgen receptor by double-stranded RNA | |
Wang et al. | Suppression of PRMT6-mediated arginine methylation of p16 protein potentiates its ability to arrest A549 cell proliferation | |
CA2579638A1 (en) | Rna interference targeting non-disease causing single nucleotide polymorphisms within a gene encoding a gain-of-function mutant huntingtin protein | |
JP2015529467A (en) | Methods and compositions for specific inhibition of MYC by double stranded RNA | |
JPWO2008139938A1 (en) | Double-stranded nucleic acid molecule targeting human papillomavirus type 16 gene and pharmaceutical comprising the same | |
Zheng et al. | MicroRNA-4651 targets bromodomain-containing protein 4 to inhibit non-small cell lung cancer cell progression | |
JP2011530289A (en) | Nucleic acid compound and its use for suppressing expression of PLK1 gene | |
US9261508B2 (en) | Antisense RNA for treating cancer and inhibition of metastasis and vectors for antisense sequestration | |
KR20210106457A (en) | Method of treating cancer overexpressing WHSC1 by inhibiting SETD2 | |
WO2010058426A2 (en) | Inhibition of vegf-a secretion, angiogenesis and/or neoangiogenesis by sina mediated knockdown of vegf-c and rhoa | |
JP6727381B2 (en) | Composition for treating cancer associated with HPV infection | |
US20100055783A1 (en) | Nucleic acid compounds for inhibiting ras gene expression and uses thereof | |
Yan et al. | BAG3 promotes proliferation of ovarian cancer cells via post-transcriptional regulation of Skp2 expression | |
Chen et al. | EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma | |
WO2006054625A1 (en) | Cancer-cell-specific cytostatic agent | |
JP4467559B2 (en) | Compositions and methods for inhibiting cell proliferation | |
Liu et al. | c‐Fos is required for TGFβ1 production and the associated paracrine migratory effects of human colon carcinoma cells | |
JP2010519913A (en) | NUCLEIC ACID COMPOUND AND USE THEREOF FOR SUPPRESSING WNT GENE EXPRESSION | |
US20110060028A1 (en) | Combination therapy | |
Pan et al. | La protein contributes to cells proliferation and migration and serves as a potential therapeutic target for hepatocellular carcinoma | |
WO2017143070A1 (en) | Combination therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08788343 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008788343 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12673813 Country of ref document: US |